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II. Abstract  
Background 
Tuberculosis is a major public health problem worldwide and is characterized by a high 
incidence in The Gambia. Children acquire infection primarily from adults in their 
households, and especially young children are at higher risk of progressing to disease and 
death. In The Gambia, childhood tuberculosis is poorly addressed in the routine national TB 
program activities; contact tracing and isoniazid preventive therapy (IPT) are not 
implemented. The burden of childhood TB is therefore poorly characterized and the 
operational challenges of implementing IPT are not well understood.  
Methods 
TB symptoms screening questionnaire and tuberculin skin testing were administered in the 
community to child contacts of adults recently diagnosed with TB. Those with TB suggestive 
symptoms and/or positive TST result were further evaluated in a dedicated clinic with 
physical examination, chest x ray, sputum induction and examination with smear, Xpert 
MTB/RIF and culture. Adherence to IPT was measured by pill count and IsoScreen test. 
Results 
Co-prevalent TB disease was detected in child contacts both within and outside immediate 
household of the adult index TB case. Altogether, 1.6% of all child contacts screened had co-
prevalent TB disease. 42.2% of the co-prevalent TB cases were among asymptomatic but 
TST positive child contacts. A combination of Xpert and culture was positive in 32.3% of all 
children diagnosed with TB, an increase of 9.7 – 22.6% over the yields from microscopy, 
Xpert and culture alone as individual tests. 255/328 (77.7%) children completed each of six 
months of IPT with good adherence. 
Conclusions 
Contact tracing restricted to symptom screening and immediate households would have 
missed nearly half of all co-prevalent TB disease in child contacts in this setting.  
A combination of Xpert and mycobacterial culture had incremental benefit for the 
bacteriological confirmation of TB disease in actively traced child contacts. Uptake of, and 
adherence to, IPT were high among the eligible child contacts.
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IV. Abbreviations 
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1. Introduction 
1.1 Brief history and global epidemiology of tuberculosis 
Tuberculosis (TB) is an ancient disease. It was believed to have been present in Egypt from 
the early dynastic times and was well recognised and clearly described by Hippocrates (1). 
However, the study of TB began during the Renaissance period when Italian scientist 
Girolamo Fracastoro recognised the contagious nature of TB (2). Concerted efforts to fight 
TB began only in late 19th century following Robert Koch’s report of the isolation of 
Mycobacterium tuberculosis (M.Tb) which established the communicable nature of TB (3). 
Since there was no definitive treatment, control efforts involved mainly bed rest, nutritional 
therapies, exposure to sunlight and isolation of patients in sanatoriums, which were located in 
rural areas(4). 
The discovery of anti-TB drugs in the 5th decade of the last century represented a watershed 
in the history of TB, with a huge drop in mortality and morbidity attributable to tuberculosis 
in the developed countries (5). However, with time, National TB Programs de-prioritized TB 
as a public health concern, due to the massive progress made as a result of use of anti-TB 
drugs and improvement in living standards, education, nutrition and industrialization. 
Additionally, the advent of HIV/AIDS in the 1980s led to a dramatic increase in the number 
of TB cases worldwide especially in sub-Saharan Africa where TB was already a major 
public health concern (6). As a result, the gains slowed and TB resurged leading to the 
declaration by the World Health Organization (WHO) in 1993 that TB had become a global 
public health emergency (7). Today, TB still remains a major global health problem, with 
around 9 million new cases and nearly 2 million deaths every year (8). Though all countries 
are affected, 85% of all TB cases occur in Africa and Asia alone, with only 22 countries 
accounting for 80% of the global TB burden (9). TB recently ranked as the 8th leading cause 
of death in low- and middle-income countries, and in those aged 15 – 59 years, ranks as the 
3rd cause of death after HIV/AIDs and Ischaemic heart disease (10). 
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1.2 Tuberculosis in Children 
TB in children is regarded as a sentinel event as children with TB are usually recently 
infected in their households by adults with sputum smear positive TB (11). Childhood TB is 
therefore a marker of ongoing TB transmission in the community. Of the 9 million TB cases 
occurring globally every year, around 1 million cases are estimated to be among children 
aged less than 15 years. In countries with low TB burden, childhood TB constitutes 
approximately 5% of the TB case load (12). In developing countries, on the other hand, little 
accurate information about childhood TB is available because of difficulty in confirming the 
diagnosis and inadequate data recording. However available data indicate that childhood TB 
may constitute 20 – 40% of the TB caseload in these countries (13, 14). Furthermore, the 
HIV epidemic led to a marked increase in incidence of TB and decrease in peak age 
prevalence of infectious TB; therefore most cases now occur in young adults who are usually 
parents of young children (15).  
Pulmonary parenchymal disease and intrathoracic lymphadenopathy are the commonest 
clinical manifestations of childhood TB and account for about 60 – 80% of cases (16). 
Among the extrapulmonary manifestations, lymphadenopathy occurs most commonly. Other 
forms of extrapulmonary TB in children include central nervous system involvement, pleural, 
pericardial, miliary and skeletal tuberculosis. 
Diagnosis of childhood TB is a huge challenge. The clinical symptoms are non-specific and 
sputum samples are difficult to obtain, especially in younger (<8 years) children. 
Furthermore, the disease is paucibacillary and, therefore, even when sputum samples are 
obtained, microbiological confirmation remains very low rarely exceeding 30% in most 
places (17).  The overwhelming majority of childhood TB are therefore clinically diagnosed 
and this has traditionally relied on the triad of close contact with a known infectious TB case, 
positive tuberculin skin test result (TST) and suggestive abnormalities on chest radiograph 
(18). These criteria, however, have limited applicability in the resource poor, high TB 
burden, settings such as The Gambia; case detection is not a routine programmatic activity 
and transmission is not limited to the household. There is therefore a glaring need for better 
control strategies for childhood TB especially in the developing countries with high TB 
burden. 
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1.3 Childhood TB in The Gambia 
The Gambia is located on the west coast of Africa with an area of around 11,300 square 
kilometers. It is bounded entirely by Senegal in the north, east and south and by the Atlantic 
Ocean in the west. The population stands currently at 1.98 million with the majority of the 
population located in the coastal areas of the country (Gambian bureau of statistics). Life 
expectancy at birth is estimated at 60 years. The Gambia is a resource-limited country with 
gross national income is 460 US dollars and poverty headcount ration of 48.5% (19). 
 In The Gambia, like in other developing country settings, childhood TB is low on the 
priority of the National Leprosy and TB Program (NLTP), diagnostic capabilities are 
inadequate and trained personnel are scarce. There is therefore paucity of data in childhood 
TB. Since 2006, the WHO has recommended that childhood TB be reported in age bands 0 - 
4 years and 5 – 15 years (20). Age disaggregation of TB data began in 2009 and only 4.4% of 
all cases of TB reported were children (NLTP Gambia data).  Majority of the childhood TB 
cases are smear positive cases diagnosed in older children (>=10years) among whom sputum 
specimen are relatively easier to collect whilst extrapulmonary TB constitute the majority of 
TB cases among the younger children.  
1.4 Control of Childhood TB 
The strategy adopted for the control of childhood Tuberculosis in endemic countries focuses 
on the identification and treatment of infectious adult TB cases and the Bacillus-Calmette 
Guerin (BCG) vaccination (21). However these methods alone remain insufficient to control 
childhood TB (22). Identification and treatment of infectious adults is the major focus of the 
Directly Observed Treatment short course (DOTS) strategy, which relies heavily on 
demonstration of M.Tb in sputum smears. However, as TB in children is paucibacillary and 
sputum specimen is difficult to obtain, the DOTS approach remains suboptimal in childhood 
TB control. In addition, children are thought to not contribute to the epidemic since they play 
little or no part in TB transmission in the community.  Childhood TB therefore remains 
relatively neglected and accorded low priority by national TB Programs. The Bacille-
Calmette-Guerin (BCG) vaccine, a live attenuated vaccine derived from Mycobacterium 
bovis, was developed in the 1920s and is in use in many countries. This vaccine does not 
protect against transmission and studies have reported a widely varying range of 0 – 80% 
protective efficacy against pulmonary TB (23). It has no proven protective effect in HIV-
infected children and might lead to BCG-disseminated disease, which is why it is now 
contraindicated in this group of children (24). Furthermore, though BCG has been shown to 
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protect against miliary TB and meningitis (25),  a large randomized controlled trial enrolling 
over 350,000 infants in southern India showed that BCG did not protect against adult 
pulmonary TB (26). In the absence of a better protective vaccine, prevention of TB through 
chemoprophylaxis of exposed individuals or treatment of latent infection with isoniazid 
(INH) represents the other feasible and beneficial approach. 
According to WHO recommendations, IPT is delivered to all children under the age of 5 who 
are evaluated during contact screening and found not to have any signs and symptoms of 
active TB. Some of these children would have evidence of latent TB infection and would 
receive IPT as curative therapy, whilst others would have no signs of M.Tb infection and 
would receive IPT purely on a prophylactic basis to prevent M.Tb infection. Given that in 
resource-poor settings asymptomatic children would not be further investigated routinely to 
distinguish between the need for treatment of latent infection or purely prophylactic 
administration of isoniazid, the term IPT is therefore used interchangeably in this thesis, in 
line with the WHO and programmatic public health practice. 
 
 The trials of treatment for latent TB infection carried out in the 1960s by Ferebee and 
colleagues showed clearly that daily administration of INH for 6 – 9 months was effective in 
preventing TB in adults and children with latent TB infection (27). More recently, a clinical 
trial of IPT among HIV infected children showed a marked reduction in TB incidence among 
those who received INH compared to those who received placebo (28). Effective contact 
tracing is required not only for early diagnosis of TB disease in child contacts but also for 
identification of those eligible for IPT. The WHO has therefore recommended that all NTPs 
screen household child contacts for TB disease and offer IPT to children <5 years in contact 
with adults with sputum smear positive TB (29), but this is currently not being done in The 
Gambia and most other resource-poor settings.  
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2. Rationale and Objectives 
2.1 Rationale 
TB is a major public health problem in the Gambia, a country with a predominantly young 
population and high TB incidence rates. A recent TB prevalence study showed a national 
prevalence of TB of 128/100,000 population and incidence of 175/100,000 population (30). 
Like in most other similar settings, childhood TB is poorly addressed in the routine national 
TB program activities. The burden of childhood TB is not well characterized, the reporting is 
extremely patchy and resources for diagnosis and management are scarce in the public health 
sector. As shown in other settings, household contact tracing and IPT among children under 5 
would likely be of significant public health impact but are currently not being implemented 
by the Gambian National Leprosy and Tuberculosis Program (NLTP). The current global 
drive to eliminate tuberculosis has increased the focus on childhood TB and it has now 
become crucial to implement the WHO recommendations especially in resource-poor high 
TB burden countries. The resources required to administer IPT to a large cohort of M.Tb 
exposed children have never been estimated in this setting and the logistical and operational 
challenges are not understood. At present, no data exists to objectively assess the challenges, 
such as adherence and provide an estimate of the costs of IPT implementation in high TB 
burden settings such as The Gambia. However, in order to implement the WHO 
recommendations, such analyses are urgently required. 
2.2 General objective 
The general objective of this PhD is therefore to implement contact tracing in households of 
adults recently diagnosed with sputum smear positive TB in the Greater Banjul Area of the 
Gambia (GBA) in order to identify co-prevalent TB cases and initiate IPT among the children 
aged less than five years in whom TB has been ruled out. 
2.3 The specific objectives are  
1. To describe the burden of childhood TB among children in contact with adult cases of 
sputum smear positive TB in households in the GBA of The Gambia 
2. To define the population of under-5 children potentially eligible for IPT and initiate 
therapy. 
3. To determine adherence to IPT using the Urine Isoscreen test 
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3. Methods 
3.1 Symptoms screening, mantoux testing, clinical examination and procedures 
Adults diagnosed with smear positive TB and reported to the NTP at the 5 leading health 
centers in the GBA were approached for consent to visit their homes and screen all children 
in the household. When consent was obtained field workers visited the homes and 
administered a standard TB symptom screening questionnaire and tuberculin skin test (TST) 
to all contacts <15years. TST was performed by the Mantoux method using 2 Tuberculin 
Units of purified protein derivative (PPD RT23 Statens Serum Institut, Copenhagen) and size 
of induration was read 48 – 72 hours later. A positive TST was defined, for all children, as 
induration of ≥10mm measured transversely, in line with WHO recommendations (20). All 
symptom positive and / or TST positive (> 10 mm) children were brought to a dedicated child 
TB clinic at the MRC Unit for clinical examination, chest x ray, sputum examination and 
HIV testing. In the clinic, detailed symptoms review, physical examination and 
anthropometric measurements were performed. Sputum was obtained from all symptomatic 
children and all asymptomatic children with abnormal chest x ray. Older (>8years) children 
provided spontaneous sputum while sputum induction was performed in younger children 
and all other children who were unable to expectorate. Trained nurses performed sputum 
induction after pre-medication with nebulized salbutamol. 
3.2 Laboratory procedures 
Sputum was collected in sterile containers and sent immediately to the TB laboratory for 
smear microscopy, GeneXpert and culture. Auramine-phenol staining was used for 
fluorescent microscopy and mycobacterial culture was done with both the MGITTM liquid 
culture system (BD, Sparks, MD, USA) and the Lowenstein-Jensen solid media. For the 
Xpert assay, 1.5ml of Xpert sample reagent was added to 0.5ml of re-suspended specimen 
sample and processed according to the manufacturer’s guidelines. 
3.3 Anti-TB treatment, isoniazid preventive therapy and adherence monitoring 
All children diagnosed with TB disease (probable or confirmed) were referred to the TB 
clinic in their catchment areas and were treated according to the national guidelines.  They 
were followed up at the MRC child TB clinic at the end of intensive phase of treatment and at 
the end of treatment. All those seen in the clinic without TB disease were treated 
appropriately. All children under-5 in the same household as the adult index case and without 
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TB disease were placed on IPT at 10mg/kg/day for 6 months. INH was provided to eligible 
children in monthly packages and daily administration was captured in a specially designed 
INH card. Field workers delivered the INH to homes of children, asked about INH side 
effects, recorded weights on the INH card and completed risk factor questionnaire at each 
visit. Adherence was assessed by pill count and by the Isoscreen urine test method among the 
children recruited in the first year of the study.  
 
All child contacts in the household without TB disease were followed up 3 monthly for a 
period of one year, independent of age. 
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4. Results 
4.1 Study 1 
Identifying children with tuberculosis amongst household contacts in The Gambia 
Egere U, Togun T, Sillah A, Mendy F, Otu J, Hoelscher M, Heinrich N, Hill PC, Kampmann 
B  (Published - International Journal of Tuberculosis and lung disease 2017; 21: 46 - 52) 
 
Abstract: 
Background: The Gambia is a high TB burden country but childhood TB is under 
recognised because of difficulties with diagnosis and low priority accorded to it by the TB 
Program.  
Methods: We implemented contact tracing to identify co-prevalent tuberculosis among child 
contacts of adults with smear positive tuberculosis in the Greater Banjul Area of the country 
where over 70% of all TB cases are diagnosed. Symptoms screening and tuberculin skin test 
(TST) were performed in the community. All symptomatic and/or TST positive child contacts 
were brought to the dedicated childhood TB clinic at the MRC where physical examination, 
chest x ray and sputum examination were performed. 
Results: Altogether, 4042 child contacts were enrolled in the study following screening in 
the community; 1772 were aged less than 5 years whilst 2270 were aged 5 years and above. 
Of the 4042, 82.6% (3339/4042) were diagnosed as TB exposed but not infected, 15.8% 
(639/4042) were latently infected and 1.6% (64/4042) had co-prevalent TB disease. Of the 64 
TB cases, 19 (29.7%) were bacteriologically confirmed while 45 (70.5%) were clinically 
diagnosed. Fifty (78.1%) of the 64 TB cases were diagnosed among child contacts in the 
same household as the adult index case whilst 14 (21.9%) were outside the household. Of 630 
asymptomatic but TST positive child contacts evaluated in the clinic, 27(4.3%) had co-
prevalent TB disease, comprising 42.8% of all TB cases diagnosed. Symptom screening 
alone would have detected only 57.8% of co-prevalent cases.  
Conclusion: This study showed that in our community setting, contact tracing detected co-
prevalent TB cases among child contacts both within and outside the household of the adult 
index case. Contact tracing restricted to symptom screening and to the index cases’ 
households would have missed nearly half of all co-prevalent TB disease in child contacts. 
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4.2 Study 2 
Contribution of Xpert MTB/RIF to the diagnosis of pulmonary tuberculosis among TB-
exposed children in The Gambia 
Togun TO, Egere UE, Sillah AK, Ayorinde A, Mendy F, Otu J, Antonio M, Sutherland J, 
Hill PC and Kampmann B. (Published – International Journal of Tuberculosis and Lung 
Disease; Vol 19, 9, 1 September 2015; pp 1091 – 1097) 
Abstract: 
Background: The WHO has recently endorsed the Xpert MTB/RIF assay for the rapid 
diagnosis of pulmonary TB and detection of rifampicin resistance. To understand the 
performance and added value of GeneXpert testing when routinely used in the context of 
active case finding among an exclusively paediatric population of TB contacts in a low 
income country, we evaluated the Xpert in children with known household exposure to a 
sputum smear positive adult TB case in The Gambia, a low HIV setting. 
Methods: One induced sputum sample was obtained from all symptomatic child contacts and 
also from asymptomatic TST positive child contacts with abnormal chest x ray. Sputum 
sample underwent fluorescent microscopy, culture and Xpert MTB/RIF assay. All the child 
contacts had HIV testing, 
Results: Four hundred and eighty seven (95%) of 514 children evaluated in the clinic had 
complete sputum smear microscopy, Xpert and culture results. Smear microscopy was 
positive in 6 (1.2%), Xpert was positive in 12 (2.5%) while culture was positive in 14 (2.9%) 
of all samples.  None of the children was HIV infected. Using culture as a reference standard, 
Xpert was positive for Mycobacterium tuberculosis in 6/14 culture positive and 6/473 
culture-negative children. This gives a sensitivity and specificity, respectively, of 42.9% 
(95%CI 17.7 – 71.1) and 98.7% (95%CI 97.2 – 99.5). Using a composite reference standard, 
“all TB diagnosis and treatment, combined Xpert and culture tests were positive for M. 
tuberculosis in 20/62 children with TB disease (32.3%, 95%CI 20.9 – 45.3) and this was 
comparable to the combined yield from microscopy, culture and Xpert (33.9%, 95%CI 22.3 – 
47.0) but significantly higher than individual yields from each test. 
Conclusion: This study shows that the number of TB cases detected by Xpert and culture 
among all children diagnosed with TB disease was comparable.  While the sensitivity of the 
Xpert test is low in actively traced child contacts, a combination of Xpert and mycobacterial 
culture has incremental benefit for the bacteriological confirmation of TB disease.
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4.3 Study 3 
Isoniazid preventive treatment among child contacts of adults with smears positive 
tuberculosis in The Gambia 
Egere U, Sillah AK, Togun TO, Kandeh S, Cole F, Adama J, Able-Thomas, A, Hoelscher M, 
Heinrich N, Hill PC and Kampmann B (Published – Public Health Action 2016;6(4):226-
231) 
Abstract 
Background: The World Health Organization recommends IPT for young children in contact 
with infectious adult TB cases. Despite its proven efficacy, IPT is not implemented in most 
high burden settings where it is needed most. We developed a home-based IPT programme 
among child contacts of adults recently diagnosed with sputum smear positive TB in The 
Gambia and assessed its impact on uptake, adherence and completion of treatment. 
Methods: Child contacts of adults with sputum smear positive TB were screened for TB 
using symptoms screening questionnaire and TST. Clinical evaluation with chest x ray and 
sputum examination was conducted to exclude TB disease. All contacts aged less than 5 
years without TB disease and in same household as the adult index case were provided 
isoniazid in their homes at 10mg/kg/day for 6 months. Adherence was measured both by pill 
count and a urine point of care colorimetric test, IsoScreen. 
Results: Of 404 under-5 contacts screened in the community, 368(91.1%) were offered IPT 
of whom 328 (89.4%) consented and commenced IPT. Altogether, 255/328 children (77.7%; 
95% CI 73.2 – 82.2) completed all 6 months with good adherence.  Among those tested with 
IsoScreen, 85.3%% of all tests among those defined as having good adherence by pill count 
were positive, compared to 16% among those defined as having poor adherence (p<0.001). 
Mothers were responsible for administering prophylaxis in 92.3% (303/328) of the cases. 
Eighteen children dropped out of prophylaxis whilst 310 children remained on prophylaxis at 
the end of the 6th month. The ‘cascade of care’ analysis showed, for all child contacts 
including those who did not start prophylaxis, an overall completion rate with good 
adherence of 61%. 
Conclusion: The study found that home-delivered IPT among child contacts of adults with 
smear positive TB in The Gambia achieved a verifiable high uptake and adherence rates. At 
national level, factors related to the system and not patient, are likely to determine success of 
IPT.
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5. Discussion 
The WHO recommends contact tracing for control of childhood tuberculosis but this is rarely 
done in most high burden countries. However, with the new ambitious goal of eliminating TB 
by the year 2035, the need to implement contact tracing has become urgent. Our first study 
reports, to the best of our knowledge, the largest single child contact tracing study in Africa 
with over 4,000 children successfully visited and screened for TB in 812 households. Sixty-
four (64) co-prevalent were diagnosed among the child contacts, giving a prevalence of 1583 
per 100,000 population of child contacts in this setting. Childhood TB is thus a huge public 
health problem in The Gambia and requires urgent control. A major opportunity from this 
study was the coverage of different subgroups of child contacts and analysis of various 
screening scenarios to provide a broad spectrum of informed choices for programmatic 
implementation of contact tracing in The Gambia and similar epidemiologic settings.  
While the WHO recommends symptom based screening for identification of children with 
TB in resource-poor settings (31), our study found that around 40% of all co-prevalent TB 
cases diagnosed were asymptomatic at the time of screening. This group of children could 
have been missed if a solely symptom based approach was adopted and TST was not 
performed. Symptoms of childhood TB can be non-specific and up to 50% of children may 
be asymptomatic at the early stages of disease (32). In The Gambia, members of the extended 
family usually live together in a cluster of homes or building located in the same piece of 
land referred to as ‘compound’. In this setting, the adult TB index case is in contact with 
children both from within and outside his immediate household. We found 14 of the 64 
(21.7%) of the co-prevalent child TB cases outside the immediate household of the adult 
index case suggesting that, for maximum impact, contact tracing in this setting must include 
all children in the compound of the index case, even if they belong to a different household. 
Again, this group of children with TB would have been missed if contact tracing were limited 
to the immediate household of the adult TB Index case. Though a ‘compound’ contact tracing 
is likely to be resource intensive, our data provides evidence to guide implementation and 
scaling up of contact tracing as resources become more available. For instance, since there is 
no added benefit in administering TST to children already symptomatic at the time of 
screening, TST could therefore be limited to the asymptomatic household contacts as more 
resources become available to the National TB Program. 
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Diagnosing childhood TB is very challenging mainly because of difficulty in obtaining 
sputum specimen and the low bacillary burden in children (33). In the light of the 
endorsement by the WHO in 2010 of the Xpert MTB/RIF assay for rapid diagnosis of 
pulmonary TB and detection of rifampicin resistance (34), our second study investigated the 
performance and added value of Xpert in the context of contact tracing among an exclusively 
paediatric population. The sensitivity of Xpert testing of one induced sputum sample was 
42.9% relative to culture-confirmed TB and this was lower than 79% and 75% respectively 
reported in hospital-based studies from Uganda (35) and Tanzania (36), both of which are TB 
high burden countries with an HIV prevalence of >40%. In South Africa, a hospital-based 
study reported a sensitivity of Xpert relative to culture-confirmed TB of 74.3% similar to 
those from Uganda and Tanzania (37) but a study in a primary care setting reported a 
sensitivity of 43.3%, similar to ours (38). Xpert thus appears to have much lower sensitivity 
in ambulant paediatric populations. This is consistent with the assumption that children with 
TB in ambulant populations have less severe disease and lower bacillary load than those 
hospitalized with TB (38, 39) but has strong implications for use as a diagnostic tool for TB 
among children in this context. However, using a composite reference standard of ‘all TB 
diagnosis and treatment’ which has a higher sensitivity than culture alone, we found a 
significantly higher incremental bacteriological yield with an increase of 9.7 – 22.6% over 
yields from microscopy, Xpert and culture alone as individual tests. A combination of 
microscopy with culture did not result in a significant incremental yield over culture alone, 
and a combination of all 3 tests – microscopy, Xpert and culture – was not significantly 
different from using Xpert and culture alone. These results support the WHO 
recommendation that Xpert be used in place of microscopy as the initial diagnostic test for 
children being investigated for TB in high burden settings (40). 
 
Given the high burden of childhood TB in The Gambia and the challenges associated with 
making both clinical and confirmed diagnosis, IPT remains a powerful tool for control of 
childhood TB. Given the high burden of childhood TB in The Gambia and the challenges 
associated with making both clinical and confirmed diagnosis, IPT remains a powerful tool 
for control of childhood TB. In the 3rd study, we implemented and evaluated a home-based 
IPT program in the greater Banjul area of The Gambia. Overall, using the pill count, 77.7% 
of all children initiating IPT completed 6 months of IPT with good adherence similar to the 
adherence of 76% in a study in Guinea Bissau where IPT was also delivered at home(41). 
However, adherence was much lower in other studies from other high burden countries – 
 17 
24% in South Africa(42), 25.6% in Indonesia (43) and 32.5% in southern Ethiopia(44). 
Interestingly, in the Ethiopian study where IPT was delivered at home, adherence was very 
poor with only 33% of children taking their medications for up to 4 months. Therefore, while 
the home delivery approach achieved high adherence in The Gambia, more site-specific 
research is required to identify the best locally applicable approach to optimized adherence. 
In The Gambia, home delivery of IPT is feasible as the health system relies heavily on 
community health workers and assistants living in the villages. These health workers could 
be trained to deliver and monitor IPT at homes of the child contacts.  Since adherence is a 
major determinant of IPT efficacy(45), we conducted a point of care urine test for adherence, 
the Isoscreen test, which detects metabolites of isoniazid in urine, to confirm the adherence 
obtained by pill counts. The excellent agreement between the adherence results from pill 
count and IsoScreen testing suggests the reliability of pill count as a means of determining 
adherence to IPT in Gambian children and increases our confidence that IPT would result in 
control of childhood TB in The Gambia. To identify where improvements may be needed in 
the continuum of care of child contacts eligible for IPT, we applied a ‘cascade of care’ 
analysis to account for all losses down the line of care which showed that approximately 61% 
of the estimated original number of contacts eligible for IPT completed 6 months of IPT with 
good adherence. This provides insight into the potential public health impact of the program, 
namely that system, and not patient, factors are likely to be the main determinants of success 
when IPT is fully taken over by the NLTP and that there are opportunities for improvement if 
IPT program is to have maximum public health impact in The Gambia. 
 
The results of these studies provide the much-needed epidemiological, clinical and public 
health baseline data to support programmatic implementation of contact tracing and other 
child TB control measures in The Gambia. Additionally, since childhood TB control efforts 
are context specific, these data could largely be generalized to other similar contexts both 
within the West African sub-region and elsewhere. 
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6. Conclusions 
Contact tracing in The Gambia detected co-prevalent TB in child contacts within and outside 
the household of the adult index cases well as among asymptomatic but TST-positive 
contacts. A symptoms-only based contact tracing would miss about 40% of all co-prevalent 
paediatric TB cases within the compound of the adult index case. 
 
The sensitivity of Xpert MTB/RIF is much lower among actively traced child contacts with 
TB disease compared to hospitalized children with TB disease. The Xpert MTB/RIF and 
culture detected a comparable number of TB cases among all children diagnosed with active 
TB disease. A combination of Xpert and mycobacterial culture gave a significantly higher 
incremental bacteriological yield over the yields from microscopy, Xpert and culture alone as 
individual tests. 
 
Uptake of, and adherence to, home delivered IPT were high by international standards among 
TB exposed Gambian children eligible for prophylaxis. IPT was highly acceptable to 
caregivers and children in The Gambia. System, not patient, factors will likely be the main 
determinants of success when IPT is transferred to be fully operational under the National TB 
Program. 
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S U M M A R Y
S E T T I N G : Greater Banjul Area of the Gambia.
O B J E C T I V E S : To identify co-prevalent tuberculosis
(TB) among child contacts of adults with smear-positive
TB.
D E S I G N : Child contacts aged ,15 years in the imme-
diate household and compound were prospectively
enrolled and evaluated for TB disease using screening
questionnaires and the tuberculin skin test (TST).
Symptomatic and/or TST-positive (710 mm) contacts
were further investigated.
R E S U LT S : Of 4042 child contacts who underwent
symptom screening and TST, 3339 (82.6%) were
diagnosed as TB-exposed but not infected, 639
(15.8%) were latently infected and 64 (1.6%) had co-
prevalent TB. Of the 64 TB cases, 50 (78.1%) were from
within the immediate household of the index case, and
14 (21.9%) from within the same compound. Of the 27
asymptomatic but TST-positive children diagnosed with
TB, 7 were microbiologically confirmed. The median
age of the TB cases was 4.4 years (interquartile range
1.9–6.9); 53.1% were aged ,5 years. Of the 4042 child
contacts, 206 (5%) slept in the same bed as the index
case; 28.1% of all TB cases occurred in this group.
Symptom screening alone would have detected only
57.8% of the co-prevalent cases.
C O N C L U S I O N : In our community setting, if contact
tracing is restricted to symptom screening and immedi-
ate households only, nearly half of all co-prevalent TB
disease in child contacts would be missed.
K E Y W O R D S : contact tracing; tuberculin skin test;
prevalence
CHILDREN acquire Mycobacterium tuberculosis
infection primarily from adults or adolescents with
smear-positive tuberculosis (TB) living in the same
household.1 Those aged ,5 years and those with
immune deficiency such as human immunodeficiency
virus (HIV) infection are at especially high risk of
developing TB disease, usually within the following 2
years.2 The World Health Organization (WHO)
therefore recommends tracing and screening of house-
hold child contacts to identify co-prevalent TB cases
and prescribe prophylactic treatment to those aged ,5
years.3,4 Although this recommendation is commonly
adopted, its implementation has been inadequate.
Apart from financial issues associated with contact
tracing, confirming TB diagnosis in children remains a
challenge,5,6 and many children continue to miss out
on preventive or curative measures.
In 2009, children aged ,15 years comprised 4.4%
of the total number of TB cases notified in The
Gambia (National TB & Leprosy Programme
[NTLP] data), much lower than the expected 10–
25%.7 In line with WHO recommendations, the
Gambian NTLP guidelines recommend contact trac-
ing within the immediate household; however, this is
not implemented. Unlike in resource-rich settings, the
tuberculin skin test (TST) does not form part of the
screening strategy. Screening efforts in The Gambia
are also further complicated by the fact that members
of the extended family commonly live together on the
same piece of land (compound) in separate but closely
located houses, with significant social mixing. TB
cases are therefore in close contact with a large group
of children within and outside their immediate
household.
We aimed to estimate the co-prevalence of TB
disease in child contacts of adult TB cases across
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Gambian compounds beyond the immediate house-
hold using an established community-based TB case
contact platform8 and symptom screening and the
TST in the community.
METHODS
Study site
The study was carried out from February 2012 to
December 2014 in the Greater Banjul Area (GBA) of
the Gambia, a mixed peri-urban, urban and rural
area, including Banjul, the capital city (population
approximately 700 000). About 70% of all TB cases
in the country are diagnosed in this area.9
Participants
Ethical approval for the study was obtained from the
joint Medical Research Council (MRC)/Gambian
government ethics committee, Banjul, The Gambia
(ref L2012.E01). Child contacts aged ,15 years
living in the same compound with sputum smear-
positive adult TB cases were recruited. A compound
was defined as a cluster of homes or buildings often
owned by members of the same family,10 and a
household as a group of individuals living in the same
building and eating from the same pot.
Symptom screening and tuberculin skin testing
After obtaining informed consent, a standard TB
symptom screening questionnaire was administered
to all children or their care givers in the compound.
Persistent unremitting cough of at least 2 weeks’
duration, with at least one other symptom such as
weight loss, failure to gain weight, fever or night
sweats, was regarded as suggestive of TB, and
contacts fulfilling these criteria were considered
symptomatic. Child contacts not fulfilling these
criteria were classified as asymptomatic. Bacille
Calmette-Guérin status was evaluated by the presence
of a typical scar. The TST was performed using the
Mantoux method (2 tuberculin units, PPD RT23
Statens Serum Institut, Copenhagen, Denmark), and
the size of the induration was read 48–72 h later. A
positive TST was defined for all children as an
induration of 710 mm measured transversely, in line
with WHO recommendations.11 TST-negative chil-
dren without symptoms of TB disease were classified
as TB-exposed but not infected.
Clinical examination and investigations
All child contacts with symptoms suggestive of TB
and/or a positive TST result were referred to a
dedicated childhood TB clinic and examined by a
paediatrician. Vital signs and anthropometric mea-
surements were obtained. All referred children
underwent chest X-ray (CXR) and HIV testing.
CXRs were read independently by two study clini-
cians, one of whom was a paediatrician, with any
discordant report assessed by a third senior paedia-
trician who was blinded to the clinical data. Sputum
was obtained if the child was symptomatic and/or had
an abnormal CXR, either spontaneously or induced
in children who were unable to expectorate.12 All
children diagnosed with TB were referred for DOTS
treatment, in line with the Gambian NLTP guidelines.
TB was defined according to WHO proposed case
definitions of bacteriologically confirmed and clini-
cally diagnosed TB (Table 1).13 TB was excluded if
the CXR was normal, there was no microbiological
confirmation and symptoms cleared spontaneously or
with conventional short-course antibiotic treatment,
regardless of TST results. TST-positive children who
were not diagnosed with TB were classified as latently
infected. All children with alternative diagnoses were
managed as appropriate.
Isoniazid prophylaxis
All contacts aged ,5 years living in the same
household as the index case and in whom TB disease
was excluded were provided with isoniazid (INH)
prophylaxis at 10 mg/kg/day for 6 months, irrespec-
tive of TST result, in line with WHO recommenda-
tions.3
Follow-up
All contacts not diagnosed with TB disease were re-
screened for symptoms every 3 months over 1 year of
follow-up in the community. Children with new
symptoms suggestive of TB were investigated as
above.
Data analysis
Categorical data were reported as frequency and
proportions. Medians and interquartile ranges (IQRs)
were calculated for non-normally distributed contin-
Table 1 Diagnostic classification according to the revised
WHO case definitions13
Confirmed TB
Detection of AFB using microscopy of
secretions, or
identification of M. tuberculosis on
culture, or
identification of M. tuberculosis using
Xpert
Clinically diagnosed TB*: Does not fulfil criteria for
bacteriological confirmation, but:
appearance on chest X-ray
suggestive of TB, and
favourable response to specific anti-
tuberculosis treatment
6 positive tuberculin skin test
6 histological appearance on biopsy
material suggestive of TB
* TB cases with symptoms and signs suggestive of TB that did not fulfil the
criteria for bacteriological confirmation of disease, had suggestive appearance
on chest X-ray and failed to respond to empirical broad-spectrum antibiotics.
Favourable response to anti-tuberculosis treatment was an integral part of the
clinical TB diagnosis.
WHO¼World Health Organization; TB¼ tuberculosis; AFB¼ acid-fast bacilli;
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uous data. Proportions of outcomes were compared
between groups using the v2 test. P , 0.05 was
considered statistically significant.
RESULTS
Characteristics of child contacts
Of 617 newly diagnosed adults with smear-positive
TB, 551 (89.3%) consented to contact tracing of
children in their households and compound; 4070
child contacts from 812 households in 346 com-
pounds were screened, giving an average of 5 child
contacts per household and 7–8 child contacts per
index case. Of these, 4042 (99.3%) had complete
screening data and were included in the analysis. The
median age was 5.9 years (IQR 2.8–9.7); females
constituted 50.8% of child contacts; 43.8% were
aged ,5 years (Table 2). Of the 705 (17.5%) TST-
positive contacts, 480/2025 (23.7%) were resident in
index case households compared to 225/2017
(11.2%) found outside of the household (P ,
0.001). Of the 4042 child contacts, 206 (5.1%)
shared the same bed with the index case. Following
screening in the community, 940/4042 (23.8%) child
contacts were referred for clinical evaluation, 909 of
whom (96.6%) attended. Only 3/909 (0.3%) children
tested HIV-positive among those examined at the
clinic. After baseline evaluation and clinical exami-
nation, 82.6% (3339/4042) of contacts were classi-
fied as exposed but not infected, 15.8% (639/4042)
were latently infected and 1.6% (64/4042) had TB
disease.
Co-prevalent disease in contacts, overall and by age
group
Overall, 64/4042 (1.6%) contacts were diagnosed
with TB: 19 (29.7%) were confirmed bacteriologi-
cally and 45 (70.3%) were diagnosed clinically.
Cough (27/45) and weight loss (23/45) were the most
common symptoms among clinically diagnosed cases,
while nearly all (42/45) had an abnormal CXR. The
median age of the TB cases was 4.4 years (IQR 1.9–
6.9); 34 (53.1%) were female (Table 2 and Figure
1A). Sixty-one TB cases completed anti-tuberculosis
treatment; 2 died while on treatment and 1 was lost to
follow-up after 2 months of treatment.
The data were analysed according to two age
groups, in line with WHO reporting standards
(Figure 1B and C). Of the 1772 contacts aged ,5
years who underwent investigation at the clinic, 34
(9.8%; 2% of all contacts) were diagnosed with TB
disease, and 8 were microbiologically confirmed.
Two of the 184 asymptomatic but TST-positive TB
cases were diagnosed on the basis of hilar lymphade-
nopathy alone. Of the 2270 contacts aged 75 years
investigated at the clinic, 30 (5%; 1.3% of all
contacts) were diagnosed with TB disease, 11 of
whom were microbiologically confirmed.
Prevalence of TB disease according to age and
proximity to index case
The prevalence of TB disease was 0.7% (14/2017)
among children living in a separate house, while it
was 1.2% (17/1448) for those in the same house but
in separate rooms, and nearly 9% (18/206) in
children sleeping in the same bed as the adult index
case (P for trend ,0.001). Of the 64 TB cases, 50
(78.1%) were diagnosed in the adult index case’s
household, while 14 (21.9%) additional cases lived in
the compound (Figure 2).
TB prevalence according to possible approaches to
contact tracing
Overall TB prevalence was 11.9% (95%CI 8.3–15.5;
Table 3) among symptomatic contacts, with the
highest prevalence (14.4%, 95%CI 9.1–19.7) among
symptomatic contacts aged ,5 years. When stratified
by household, prevalence of TB disease was 2.5%
(95%CI 1.8–3.2) among child contacts within the
household compared to 0.7% (95%CI 0.3–1.1) of
cases diagnosed outside the household of the index
case. TB was diagnosed in 6.2% (44/705) of all TST-
positive children, compared to 0.6% (20/3337) of
TST-negative children. Among asymptomatic but
TST-positive contacts, TB prevalence was 4.3%
(95%CI 2.7–5.9).
Three-monthly follow-up
Of 3102 initially asymptomatic and TST-negative
child contacts, 46 (1.5%) developed symptoms
during follow-up and 3 were clinically diagnosed
with TB disease: 2 at the first follow-up (in a 21-
month-old female who was not eligible for IPT and a
Table 2 Characteristics of child contacts of adult smear-
positive TB screened in the community
Characteristics (n ¼ 4042) n (%)
Age, years, median [IQR] 5.9 [2.8–9.7]
Females 2056 (50.9)
Symptomatic 310 (7.6)
Contacts aged ,5 years 1772 (43.8)
BCG scar present (n ¼ 1637) 1418 (86.6)
TST 7 10 mm 705 (17.5)
Relationship to index case
Child 540 (13.4)
Sibling 301 (7.5)
Other relation 2118 (52.4)
Not related 1083 (26.8)
Proximity to index case
Separate house 2017 (49.9)
Same house but separate room 1448 (35.8)
Same room but separate bed 371 (9.2)
Same bed 206 (5.1)
Attended clinic 909 (22.5)
TB diagnosis 64 (1.6)
Bacteriological confirmed 19 (0.5)
Clinically diagnosed 45 (1.1)
Not TB 830 (20.5)
TB¼ tuberculosis; IQR¼ interquartile range; BCG¼ bacille Calmette-Guérin;
TST¼ tuberculin skin test.
48 The International Journal of Tuberculosis and Lung Disease
Figure 1 A) Flow chart of baseline screening, clinical examination and outcome of all child
contacts. B) Flow chart of baseline screening, clinical examination and outcome of child contacts
aged ,5 years. C) Flow chart of baseline screening, clinical examination and outcome of child
contacts aged 75 years. TST ¼ tuberculin skin test; LTBI ¼ latent tuberculous infection; TB ¼
tuberculosis.
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34-month-old male who was prescribed but did not
undergo IPT), and an 11-year-old boy in the last
month of follow-up.
DISCUSSION
To the best of our knowledge, this is the largest child
contact tracing study reported from Africa, with over
4000 child contacts from 812 TB-affected house-
holds, enabling in-depth analysis of different sub-
groups and screening scenarios. Overall, 15.8% of
contacts were latently infected and 1.6% had TB
disease. There were 64 co-prevalent and three
incident cases. While TB disease was more prevalent
among symptomatic contacts regardless of age, 40%
of the TB cases were nevertheless diagnosed among
asymptomatic child contacts who were referred for
further investigations due to TST positivity. Over
three quarters of the co-prevalent TB cases were
among contacts who lived in the immediate house-
hold of the adult index case. A third of cases arose
from young child contacts who shared a bed with the
index case. These findings might call into question an
exclusively symptom-based approach to contact
tracing in children and help policy makers define
priorities for contact screening.
Only 1.6% of the study child contacts were found
to have TB, increasing to 2.3% in contacts living
within the index case households. These percentages
are lower than the 7% reported from a pooled
analysis of contact studies in middle- and low-income
countries,14 but comparable to our previous study
from The Gambia.15 A study from Indonesia found
TB disease in 7.8% of child contacts, but none were
bacteriologically confirmed,16 while in Uganda, 10%
of the contacts were diagnosed with TB; all child
contacts were investigated in the clinic and 3% of
children were HIV-positive (as opposed to 0.3% in
our cohort in The Gambia).17 Our rate of microbi-
ological confirmation among diagnosed cases
(29.7%) was similar to those found by other
investigators.18,19
Symptom-based screening as recommended by the
WHO3 facilitates the identification of TB in children
in resource-poor settings and has a high negative
predictive value for TB disease.16,20 Nearly 60% of
all co-prevalent TB cases identified in our study were
symptomatic. However, 40% of co-prevalent TB
cases occurred in asymptomatic children, and sole
reliance on a symptom-based approach would have
missed these entirely.
Symptoms of childhood TB can be non-specific,
and up to 50% of children may be asymptomatic in
the early stages of the disease.21 The TST led to the
identification of 630 asymptomatic but TST-positive
child contacts in our study, 4.3% of whom were
diagnosed with TB, including seven who were
bacteriologically confirmed. In a much smaller
contact tracing study from South Africa also employ-
ing TST and CXR, microbiologically confirmed TB
was diagnosed among 1.4% (9/644) of children aged
,5 years, 7 of whom were asymptomatic but had an
Figure 2 Distribution of co-prevalent cases within the
compound. TB ¼ tuberculosis; TSTþ ¼ tuberculin skin test-
positive.
Table 3 Prevalence of TB disease by approach to contact tracing
Approach to screening n
TB cases
n Prevalence (95%CI) Prevalence/100 000 population
All child contacts 4 020 64 1.6 (1.2–1.9) 1 583.4
Symptomatic 310 37 11.9 (8.3–15.5) 11 935.5
Asymptomatic TST-positive 630 27 4.3 (2.7–5.9) 4 285.7
Within household 2 025 50 2.5 (1.8–3.2) 2 469.1
Outside household 2 017 14 0.7 (0.3–1.1) 694.1
Asymptomatic TST-negative 3 102 0 0
Aged ,5 years
All 1 772 34 1.9 (1.3–2.6) 1 918.7
Symptomatic 167 24 14.4 (9.1–19.7) 14 371.3
Asymptomatic TST-positive 192 10 5.2 (2.1–8.3) 5 208.3
Within household 898 29 3.2 (2.1–4.4) 3 118
Outside household 874 5 0.6 (0.1–1.1) 572.1
Aged 75 years
All 2 270 30 1.3 (0.9–1.8) 1 321.5
Symptomatic 143 13 9.0 (4.4–13.7) 9 090
Asymptomatic 438 17 3.9 (2.1–5.0) 3 881
Within household 1 127 21 1.9 (1.1–2.7) 1 863
Outside household 1 143 9 0.8 (0.3––1.3) 787
TB¼ tuberculosis; CI¼ confidence interval; TST¼ tuberculin skin test.
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abnormal CXR.22 Although the TST was performed
in 94% of these children, TB prevalence in TST-
positive vs. TST-negative children was not reported in
that study. In our study, TB disease was 10 times more
common in TST-positive than in TST-negative chil-
dren.
The size of our cohort enables us to provide robust
estimates of the yield from different screening
approaches in the community, assuming the avail-
ability of TST. First, there is no added benefit from
conducting TST in children who are already symp-
tomatic at the time of screening, as they will be
investigated for disease anyway. A negative TST does
not exclude TB disease.3 Second, noting the very low
yield during the 12-month follow-up, there is little or
no benefit from screening asymptomatic children
who are TST-negative any further for TB disease.
Restricting screening to the immediate household of
the adult index case yielded 78% of the co-prevalent
TB cases in our study. Independent of household or
compound, restricting screening to children who
shared a bed with the index case would have yielded
28% of the TB cases.
Given the ambitious new WHO End TB Strategy,
which includes early detection and treatment of all
patients with TB,23 adequately resourced TB pro-
grammes may consider screening children outside of
the immediate household of an index case, especially
in a setting such as The Gambia. Here we have
provided estimates of the yield from such screening
approaches, with 21% of all co-prevalent cases found
among contacts in the wider compound who would
not have been included had contact tracing exclu-
sively focused on the immediate household. While the
prevalence rate in the wider compound was less than
a third that found in the immediate households, we
estimate that it was at least three times that in the
general community (2014 NLTP TB prevalence
survey data, personal communication), making these
children a relatively high-risk, high-yield group for
active case finding.
Our study had some limitations. As no further
routine investigations of asymptomatic TST-negative
contacts were conducted, the actual burden of
childhood TB in this population may have been
underestimated. Unlike recommendations in some
European guidelines,24 we did not perform a repeat
TST in TST-negative children in any group. Second,
our definition of suggestive symptoms was very
restrictive and may have precluded eligible children
from further evaluation. However, as outlined above,
the regular follow-up of the entire cohort would most
likely have picked up incident cases, as 90% of TB
disease in children is known to develop within the
first 12 months of a significant household exposure.25
In conclusion, contact tracing in this West African
setting helped detect TB in child contacts both within
and outside the household of the adult index case, and
a significant proportion of co-prevalent TB was found
among asymptomatic but TST-positive contacts. In
settings such as The Gambia, a symptoms-only based
contact tracing approach targeting only child con-
tacts within the immediate household of the adult
index case could detect the majority of co-prevalent
child TB cases, but would miss about one fifth of all
co-prevalent TB within the compound. Our data
support the view that where TST is available as a
screening tool, it should be applied to asymptomatic
household contacts only. Further studies are now
required to assess the cost-effectiveness of such a
contact tracing strategy in The Gambia and similar
settings.
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R E S U M E
C O N T E X T E : Région du Grand Banjul en Gambie.
O B J E C T I F : Identifier la tuberculose (TB) co-prévalente
parmi des enfants contacts d’adultes atteints de TB à
frottis positif.
S C H É M A : Les enfants (âge ,15 ans) contacts dans la
famille immédiate et dans la concession ont été enrôlés
de façon prospective et évalués vis-à-vis de la TB grâce à
des questionnaires de dépistage et un test cutané à la
tuberculine (TST). Les contacts symptomatiques et/ou
ayant un TST positif (710 mm) ont bénéficié d’autres
investigations.
R É S U LT A T S : Ont eu un dépistage 4042 enfants
contacts basé sur les symptômes et un TST. Parmi eux,
3339 (82,6%) ont été considérés comme exposés à la TB
mais pas infectés, 639 (15,8%) avaient une infection
latente et 64 (1,6%) avaient une TB co-prévalente. Sur
les 64 cas de TB, 50 (78,1%) ont été diagnostiqués dans
la famille immédiate du cas index et 14 (21,9%) au sein
de la concession. Vingt-sept enfants asymptomatiques
mais ayant un TST positif ont eu un diagnostic de TB,
dont sept ont été confirmés par la microbiologie. L’âge
médian des cas de TB a été de 4,4 (intervalle
interquartile 1,9–6,9) ans ; 53,1% avaient moins de 5
ans. Cinq pour cent (n ¼ 206) des contacts dormaient
dans le même lit que le cas index et 28,1% de tous les cas
de TB sont survenus dans ce groupe. Le dépistage des
symptômes seul aurait détecté seulement 57,8% des cas
co-prévalents.
C O N C L U S I O N : Dans le contexte de notre
communauté, la recherche de contacts restreinte au
dépistage des symptômes dans la famille immédiate
aurait laissé passer près de la moitié des cas de TB
maladie co-prévalente chez les enfants contacts.
R E S U M E N
M A R C O D E R E F E R E N C I A: La zona del Gran Banjul en
Gambia.
O B J E T I V O S: Detectar la prevalencia concomitante de
tuberculosis (TB) en los niños que son contactos de los
adultos con TB y baciloscopia positiva.
M É T O D O: Se investigó la presencia de enfermedad
tuberculosa en los niños (menores de 15 años) que
tenı́an un contacto inmediato o en el complejo
domiciliario con un caso de TB, mediante
cuestionarios de tamizaje y la prueba cutánea de la
tuberculina (TST). Los contactos sintomáticos o con un
resultado positivo de la TST se examinaron de manera
más completa.
R E S U LTA D O S: Se practicó la detección sistemática
mediante la investigación de los sı́ntomas y la TST en
4042 niños definidos como contactos. Se puso en
evidencia una exposición a la TB sin infección en el
3339 (82,6%), una infección tuberculosa latente en el
639 (15,8%) y el 64 (1,6%) de los niños presentó TB. De
los 64 casos de TB, 50 (78,1%) se diagnosticó en el
domicilio inmediato del caso inicial y 14 (21,9%) en el
complejo domiciliario. Se diagnosticó TB en 27 niños
asintomáticos, pero con un resultado positivo de la TST,
de los cuales se logró la confirmación bacteriológica en
siete casos. La mediana de la edad de los casos de TB fue
4,4 años (intervalo intercuartil 1,9–6,9); el 53,1% era de
edad de ,5 años. El 5% de los contactos (n ¼ 206)
dormı́a en la misma cama del caso inicial y el 28,1% de
todos los casos de TB ocurrió en este grupo. La
investigación exclusiva de los sı́ntomas solo habrı́a
detectado el 57,8% de los casos prevalentes
concomitantes.
C O N C L U S I Ó N: En el entorno de la comunidad
estudiada, una investigación de contactos limitada a la
detección de sı́ntomas y al domicilio inmediato habrı́a
pasado por alto cerca de la mitad de los casos
concomitantes de enfermedad tuberculosa en los niños
que son contacto de un caso adulto.
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S U M M A R Y
S E T T I N G : Greater Banjul Area, The Gambia.
O B J E C T I V E : To conduct a pragmatic evaluation of the
Xpertw MTB/RIF assay in the diagnosis of tuberculosis
(TB) among child contacts.
D E S I G N : In this prospective study, one induced sputum
sample was obtained from TB contacts aged ,15 years
and tested using fluorescent microscopy, culture and
Xpert. The diagnostic accuracy of the microbiological
tests was evaluated against culture and ‘all TB diagnosis
and treatment’ as separate reference standards.
R E S U LT S : Using culture as a reference standard, Xpert
was positive for Mycobacterium tuberculosis in 6/14
culture-positive and 6/473 culture-negative children,
giving a sensitivity and specificity of respectively 42.9%
(95%CI 17.7–71.1) and 98.7% (95%CI 97.2–99.5).
With ‘all TB diagnosis and treatment’ as a composite
reference standard, combined Xpert and culture tests
were positive for M. tuberculosis in 20/62 children with
TB disease (32.3%, 95%CI 20.9–45.3), which was
comparable to the yield from microscopy, culture and
Xpert combined (33.9%, 95%CI 22.3–47.0), but
significantly higher than individual yields from each test.
C O N C L U S I O N : The sensitivity of Xpert is low in
actively traced child contacts, but a combination of
Xpert and mycobacterial culture has incremental bene-
fits for the bacteriological confirmation of TB disease.
K E Y W O R D S : accuracy; Xpertw MTB/RIF; child con-
tacts
EACH YEAR, AROUND HALF a million children
aged ,15 years become ill with tuberculosis (TB),
resulting in up to 70 000 deaths.1 However, the true
burden of disease remains unknown, mostly due to
difficulties with the diagnosis of TB in children.
Childhood TB mimics other diseases such as pneu-
monia, human immunodeficiency virus (HIV) infec-
tion and malnutrition.2 Younger children rarely
produce good quality respiratory specimens, and TB
is associated with a low bacillary burden in chil-
dren.3,4 The bacteriological confirmation of TB
disease in children therefore seldom exceeds
30%,5,6 and the diagnosis of childhood TB is mostly
presumptive.7
In 2010, the Xpertw MTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) was endorsed by the World
Health Organization (WHO) for the rapid diagnosis
of pulmonary TB and detection of rifampicin (RMP)
resistance;8 however, data on its diagnostic accuracy
in children are still emerging. In adult studies, the
specificity of Xpert is comparable to that of liquid
culture, while its sensitivity is relatively higher in
smear- and culture-positive TB than in smear-
negative, culture-positive TB cases.9,10 Studies in
children, mostly hospital-based, have reported vari-
able sensitivity and high specificity of the Xpert test in
the detection of Mycobacterium tuberculosis.11–18
Given emerging concerns about the feasibility and
cost-effectiveness of decentralised Xpert testing in
high TB burden settings,19 understanding the added
value of Xpert testing when used routinely in a variety
of contexts is important.20,21
Children exposed to adults with sputum smear-
positive TB have a high likelihood of developing
active TB themselves, and should be investigated for
TB.22 Although recommended, screening of child
contacts is rarely performed in resource-constrained,
high TB burden countries.23 As far as we are aware,
no study has investigated the performance and added
value of Xpert in an active case-finding study among
an exclusively paediatric population of TB contacts in
a low-income country. We therefore evaluated Xpert
in children with known household exposure to a
sputum smear-positive adult TB case in a low HIV
prevalence setting in West Africa.
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STUDY POPULATION AND METHODS
Study setting
This prospective study was conducted at the Medical
Research Council (MRC) Unit – The Gambia, located
in the urban Greater Banjul Area (GBA), from where
an estimated 80% of all TB cases in the country are
notified. In 2013, TB incidence rate in The Gambia
was 173 cases per 100 000 population, while HIV
prevalence among adults aged 15–49 years was
1.3%.24,25
Ethics approval for the study was obtained from
the Gambia Government/MRC Joint Ethics Commit-
tee, Banjul, The Gambia.
Contact tracing and clinic procedure
Paediatric household contact tracing was conducted
from February 2012 to July 2014. Consecutively
diagnosed adult smear-positive index TB cases,
identified within the Gambia National TB Control
Programme (NTCP), were visited in their compounds
for the screening of household contacts aged ,15
years. Following written informed consent from the
parent/guardian of the respective child, children were
recruited and screened for disease using a standard-
ised symptom screening questionnaire and tuberculin
skin test (TST). In the clinical screening algorithm,
symptoms suggestive of TB were defined as unremit-
ting cough of .14 days and at least one of either
fever, weight loss/failure to thrive, malaise/fatigue,
haemoptysis, night sweats or enlarged cervical lymph
nodes. A positive TST was defined as transverse skin
induration 710 mm, regardless of bacille Calmette-
Guérin vaccination status, measured 48–72 h after
intradermal injection of 0.1 ml of two tuberculin
units of purified protein derivative (Statens Serum
Institute, Copenhagen, Denmark) in the volar aspect
of the left forearm. All children aged ,15 years with
symptoms suggestive of TB and/or positive TST
results were referred to the MRC childhood TB clinic
for further evaluation.
Evaluation at the clinic by study paediatricians
included a detailed symptom review, physical exam-
ination and anthropometric measurements that in-
cluded calculation of the height-for-age Z-score
(HAZ) using the WHO 2007 reference standards.26
All children referred to the clinic underwent HIV
testing and a chest X-ray (CXR) that was read
independently by two study physicians, with any
discordant report assessed by a third senior clinician
who was blinded to the clinical data. Sputum
induction was requested for all children aged 73
months with symptoms suggestive of TB and/or an
abnormal CXR. A single induced sputum sample was
requested per patient, taking into consideration the
practical issues of the procedure, including the cost of
materials and the extent of discomfort for the
children. A trained study nurse performed sputum
induction using nebulised hypertonic saline (3%)
after fasting for at least 3 h and premedication with
nebulised salbutamol, obtaining a sample of at least
2.5 ml. Sputum samples were collected in sterile
containers and sent immediately to the onsite TB
diagnostic laboratory for pathogen detection tests.
TB disease was defined according to the case
definitions proposed by the WHO, comprising
bacteriologically confirmed or clinically diagnosed
TB cases (Table 1).27 All subjects diagnosed with TB
disease were referred for standard 6-month anti-
tuberculosis treatment according to national guide-
lines.28 Children without bacteriological confirma-
tion or radiological signs of TB disease and with
resolution of symptoms either spontaneously or with
conventional short-course antibiotic treatment were
treated for respiratory infections other than TB.
All child contacts were followed up at home by
trained field workers at 3-month intervals for 12
months, with repeated symptom screening and clinic
visits if the child became unwell. Children initially
diagnosed with TB disease underwent clinic follow-
up at 2 months and at the end of anti-tuberculosis
treatment, with evaluation of their response to
treatment.
Laboratory procedures
Induced sputum samples were processed within 2 h of
collection by trained laboratory technicians blinded
to the clinical data (Appendix).* Briefly, samples
were digested and decontaminated as previously
described,29 and the concentrated sediments were
re-suspended in 1.5 ml of phosphate buffer. The re-
suspended sediments were simultaneously processed
for fluorescence microscopy after auramine-phenol
staining and mycobacterial culture with both
MGITe liquid culture system (BD, Sparks, MD,
USA) and Löwenstein-Jensen (LJ) solid media using
standard laboratory procedures as previously de-
scribed.30 For the Xpert assay, 1.5 ml of the Xpert
sample reagent was added to 0.5 ml of re-suspended
sediment sample and processed according to the
manufacturer’s guidelines.31
Statistical analysis
The diagnostic accuracy of the microbiological tests,
including Xpert, was assessed by comparing the
results with mycobacterial culture as the primary
reference standard, and with a composite reference
standard of ‘all TB diagnosis and treatment’ based on
clinical, radiological and microbiological findings,
comprising both bacteriologically confirmed and
clinically diagnosed TB cases. The data were analysed
on a per-patient basis: the results of all pathogen
* The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2015/
00000019/00000009/art00018
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detection tests for each patient were combined into a
single test result that was deemed positive when at
least one positive result was obtained for a specific
microbiological test. The McNemar’s test was used to
compare the performance of the microbiological tests
individually or in combination. All statistical analyses
were carried out using STATA, version 13 (Stata
Corp, College Station, TX, USA). P , 0.05 (2-sided)
was considered statistically significant.
RESULTS
Overall, 3298 child contacts of 622 consecutive adult
index TB cases were recruited and screened in 952
households. Of these, 873 contacts were seen and
investigated at the MRC childhood TB clinic (Figure
1). One induced sputum sample was obtained from
514 children with symptoms suggestive of TB or with
an abnormal CXR, of which 487 (95%) with
complete sputum smear microscopy, Xpert and
culture results were included in this analysis.
The median age of the 487 child contacts was 6
years (interquartile range 3–9); none were HIV-
infected (Table 2). Smear microscopy was positive
in 6 (1.2%), Xpert was positive in 12 (2.5%) and
culture was positive in 14 (2.9%). Overall, 62
patients were diagnosed with active TB disease and
started on standard anti-tuberculosis treatment: 21
(4%) were bacteriologically confirmed, while 41
(8%) were clinically diagnosed with TB with no
positive microbiological tests. Four hundred and
twenty-five contacts (88%) were diagnosed and
treated for other respiratory diseases. Using culture
as reference standard, smear microscopy was positive
for acid-fast bacilli in 4/14 culture-positive cases
(28.6%, 95% confidence interval [CI] 8.4–58.1),
while Xpert was positive for M. tuberculosis in 6/14
culture-positive and 6/473 culture-negative patients,
giving a sensitivity and specificity of respectively
42.9% (95%CI 17.7–71.1) and 98.7% (95%CI
97.2–99.5) (Table 3). Xpert detected all four smear-
and culture-positive cases and 3/10 (30%, 95%CI 7–
65) smear-negative, culture-positive TB cases.
When using ‘all TB diagnosis and treatment’ as a
composite reference standard, the sensitivity of Xpert
was 19.4% (95%CI 10.4–31.4), significantly higher
than that of smear microscopy (9.7%, 95%CI 3.6–
19.9, P ¼ 0.042), but comparable to that of culture
(22.6%, 95%CI 12.9–35.0, P ¼ 0.598) (Table 4).
Figure 2 depicts the yields from smear microscopy,
Xpert and culture as individual tests and in combi-
nations. Xpert and culture combined were positive
for M. tuberculosis in 20/62 children with active TB
disease, giving a sensitivity of 32.3% (95%CI 20.9–
45.3), which was significantly higher than the
sensitivity of smear microscopy (P , 0.001), Xpert
(P ¼ 0.005) and culture (P ¼ 0.031) when used as
individual tests (Table 4). The bacteriological yield
from combining the results of smear microscopy and
culture was not significantly different from culture
alone (P ¼ 0.157), while the yield from the
combination of the three tests (smear microscopy,
Xpert and culture) was not significantly different
from using only Xpert and culture together (P ¼
0.317). No RMP resistance was detected in any of the
samples analysed.
DISCUSSION
In this study, we report the evaluation of Xpert
among TB-exposed children identified from a house-
hold contact tracing project in The Gambia. Xpert
testing of one induced sputum sample had a
sensitivity of 42.9% relative to culture-confirmed
TB, with a specificity of 98.7% among children
without TB, while its sensitivity was 19.4% when
compared to a composite reference standard of ‘all
TB diagnosis and treatment’.
In line with previous reports, the sensitivity of
Xpert in our study was higher than that of smear
microscopy, with relatively higher sensitivity in
smear- and culture-positive TB cases than in smear-
negative, culture-positive TB cases. However, we
found that the sensitivity of Xpert relative to culture
was lower than that reported in hospital-based
studies from other high TB burden settings such as
Uganda and Tanzania, where Xpert detected 79%
and 75% of culture-confirmed TB, respectively, in
populations with an HIV prevalence of .40%, while
another hospital-based paediatric cohort from South
Table 1 TB disease according to the revised WHO case definitions
Bacteriologically confirmed TB Detection of AFB using microscopy of secretions; or
Identification of M. tuberculosis using culture; or
Identification of M. tuberculosis using a WHO-approved rapid
diagnostic such as XpertW MTB/RIF
Clinically diagnosed TB* Does not fulfil criteria for bacteriological confirmation; but
Suggestive appearances on chest X-ray; and
Favourable response to specific anti-tuberculosis treatment; and/or
Positive tuberculin skin test;
Suggestive histological appearances on biopsy material
* Clinically diagnosed TB cases had symptoms and signs suggestive of TB, did not fulfil the criteria for bacteriological
confirmation of disease, had suggestive appearance on chest X-ray and failed to respond to empirical broad spectrum
antibiotics. A favourable response to anti-tuberculosis treatment was an integral part of the clinical TB diagnosis.
TB¼ tuberculosis; WHO¼World Health Organization; AFB¼ acid-fast bacilli.
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Africa similarly reported a sensitivity of 74.3% for
Xpert testing of at least one induced sputum
sample.11,13,14 The sensitivity of Xpert in our study
is comparable to the findings from another paediatric
South African study that reported a sensitivity of
43.3% with Xpert relative to culture in a primary
care setting,18 while a recent systematic review of 15
studies on Xpert accuracy in children reported a
pooled sensitivity of 48% in out-patient studies
compared to 70% in in-patient studies.32 Taken
together, these figures are consistent with the as-
sumption that children with TB in ambulant popu-
lations have less severe disease and lower bacillary
load than children hospitalised with TB.18,19 The
sensitivity of Xpert thus appears to be substantially
lower in ambulant populations, which has strong
implications for its use as a diagnostic tool for TB
among children in this context. This conclusion is
Figure 1 Study profile: recruitment and diagnostic classification of study subjects. TB ¼
tuberculosis; TST¼ tuberculin skin test; INH¼ isoniazid; CXR¼ chest X-ray.
Table 2 Demographic and clinical characteristics stratified by diagnosis (confirmed, clinically diagnosed TB and not TB)
Characteristics
Total
(n ¼ 487)
n/N (%)
Confirmed TB
(n ¼ 21)
n/N (%)
Clinically diagnosed TB
(n ¼ 41)
n/N (%)
Not TB
(n ¼ 425)
n/N (%) P value
Age, years, median [IQR] 6 [3–9] 6 [3–11] 3.8 [2–6] 6 [3–9] 0.020*
Male sex 259/487 (53) 6/21 (29) 22/41 (54) 231/425 (54) 0.069
Cough and/or fever 72 weeks 374/487 (77) 21/21 (100) 34/41 (83) 319/425 (75) 0.019*
Chest X-ray abnormal 358/482 (74) 17/21 (81) 38/41 (93) 303/420 (72) 0.013*
BCG scar present 332/460 (72) 14/20 (70) 29/40 (73) 289/400 (72) 0.975
TST 710 mm 243/398 (61) 8/16 (50) 26/35 (74) 209/347 (62) 0.174
Anthropometry
BMI-for-age Z-score ,2 SD 137/480 (29) 10/21 (48) 12/41 (29) 115/418 (27) 0.137
Height-for-age Z-score ,2 SD 63/481 (13) 2/21 (10) 5/41 (12) 56/419 (14) 0.864
* Statistically significant.
TB¼ tuberculosis; IQR¼ interquartile range; BCG¼ bacille Calmette-Guérin; TST¼ tuberculin skin test; BMI¼ body mass index; SD¼ standard deviation.
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further supported by the overall Xpert and culture
positivity rates of respectively 2.5% and 2.9% in our
study, which were much lower than the 14–17%
reported for both microbiological tests in hospital-
based studies.11,14 We also reported six Xpert-
positive but culture-negative cases who were classi-
fied and treated as bacteriologically confirmed TB
cases. The six cases had symptoms suggestive of TB,
abnormal CXR, no past history of anti-tuberculosis
treatment and a high background risk of disease,
given their recent exposure to an adult with infectious
TB in the household setting. These factors, taken
together with the very high specificity of Xpert in
children without TB, makes them very likely to be
true-positive TB cases, and this is supported by the
fact that at least five of the six children (one missed
the 2-month follow-up) had an increase in weight of
at least 5% after 2 months of anti-tuberculosis
treatment.
The fact that culture has generally low sensitivity in
children due to the paucibacillary nature of childhood
TB makes it an imperfect reference standard, as
recently discussed in detail by Cuevas et al.33 We
therefore chose to also assess the sensitivity and
specificity of the microbiological tests using a
composite reference standard of ‘all TB diagnosis
and treatment’, which will have a higher sensitivity
than culture alone. We found that the combination of
Xpert and culture was positive in 32.3% of all
children diagnosed with TB, giving a significantly
higher incremental bacteriological yield, with an
increase of 9.722.6% over the yields from micros-
copy, Xpert and culture alone as individual tests. It
should be noted that combining microscopy with
culture gave no significant incremental yield over
culture alone, and the yield from the combination of
the three tests (microscopy, Xpert and culture) was
not significantly different from that using only Xpert
and culture together. These results support the recent
WHO recommendation that Xpert be used in place of
smear microscopy as the initial diagnostic test for
investigating children presumed to have TB in high-
burden settings.34 Although the impact of Xpert from
an operational perspective is best addressed in large
cohort studies, preferably within national TB pro-
grammes, our results suggest that in settings where
presumptive treatment of TB in children is common,
combining Xpert testing with culture methods has
strong incremental value for bacteriological confir-
mation of TB diagnosis in children, and should be
encouraged where feasible.
While Xpert testing of multiple similar or different
specimens has been shown to increase the bacterio-
logical yield in children presumed to have TB in
research settings,11,13,17,18 studies on the feasibility
and cost-effectiveness of such an approach in
resource-limited settings are required. Our study has
some limitations. We identified a relatively small
number of culture-confirmed TB cases from investi-
gating almost 500 children, as reflected by the broad
95%CIs of test sensitivity compared to culture;
however, this also emphasises the challenge of
bacteriological confirmation of disease in children.
Furthermore, the inclusion of the microbiological
tests under investigation in the composite reference
standard could result in incorporation bias that may
Table 4 Accuracy of microbiological tests using ‘all TB diagnosis and treatment’ as a composite reference standard
Diagnostic test
Sensitivity
n/N (%) (95%CI)
Specificity
n/N (%) (95%CI)
PPV
n/N (%) (95%CI)
NPV
n/N (%) (95%CI)
Sputum smear microscopy 6/62 (9.7)
(3.6–19.9)
425/425 (100)
(99.1–100.0)
6/6 (100)
(54.1–100.0)
425/481 (88.4)
(85.2–91.1)
XpertW MTB/RIF 12/62 (19.4)
(10.4–31.4)
425/425 (100)
(99.1–100.0)
12/12 (100)
(73.5–100.0)
425/475 (89.5)
(86.4–92.1)
Culture 14/62 (22.6)
(12.9–35.0)
425/425 (100)
(99.1–100.0)
14/14 (100)
(76.8–100.0)
425/473 (89.9)
(86.8–92.4)
Sputum smear microscopyþculture 16/62 (25.8)
(15.5–38.5)
425/425 (100)
(99.1–100.0)
16/16 (100)
(79.4–100.0)
425/471 (90.2)
(87.2–92.8)
Xpertþculture 20/62 (32.3)
(20.9–45.3)
425/425 (100)
(99.1–100.0)
20/20 (100)
(83.2–100.0)
425/467 (91.3)
(88.4–93.6)
SputumþXpertþculture 21/62 (33.9)
(22.3–47.0)
425/425 (100)
(99.1–100.0)
21/21 (100)
(83.9–100.0)
425/466 (91.2)
(88.3–93.6)
TB¼ tuberculosis; CI¼ confidence interval; PPV¼ positive predictive value; NPV¼ negative predictive value.
Table 3 Accuracy of microbiological tests with mycobacterial culture as reference standard
Diagnostic test
Sensitivity
n/N (%) (95%CI)
Specificity
n/N (%) (95%CI)
PPV
n/N (%) (95%CI)
NPV
n/N (%) (95%CI)
Sputum smear
microscopy 4/14 (28.6) (8.4–58.1) 471/473 (99.6) (98.5–100.0) 4/6 (66.7) (22.3–95.7) 471/481 (97.9) (96.2–99.0)
XpertW MTB/RIF 6/14 (42.9) (17.7–71.1) 467/473 (98.7) (97.2–99.5) 6/12 (50.0) (21.1–78.9) 467/475 (98.3) (96.7–99.3)
CI¼ confidence interval; PPV¼ positive predictive value; NPV¼ negative predictive value.
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have overestimated test performance. However, even
with possible overestimation, the sensitivity of Xpert
and culture as standalone tests relative to the
composite reference standard was only 19.4% and
22.6%, respectively. Furthermore, we obtained only
one induced sputum sample per child and as such
could not assess the incremental value of multiple
testing.
CONCLUSION
The sensitivity of Xpert and the overall bacteriolog-
ical yield, known to be generally lower in children
than in adults, were even lower in actively traced
child contacts than in hospital-based studies. Xpert
and culture detected a comparable number of TB
cases among all children diagnosed with active TB.
Culture of respiratory specimens is still advisable if
available because, unlike smear microscopy, it has
incremental benefits when combined with Xpert
testing.
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APPENDIX
LABORATORY PROCEDURES
Induced sputum samples were processed within 2 h of
collection by trained laboratory technicians. Samples
were digested and decontaminated using N-acetyl-L-
cysteine and sodium hydroxide (1% final concentra-
tion), as previously described by Kent and Kubica,25
with a contact time of 15 min; the concentrated
sediments were resuspended in 1.5 ml phosphate
buffer. An aliquot of the concentrated sediments was
simultaneously prepared for fluorescent acid-fast
smear microscopy following auramine-phenol stain-
ing, as well as both liquid and solid mycobacterial
culture, as previously described.26 For liquid culture,
0.5 ml of re-suspended sediment was inoculated into
Mycobacteria Growth Indicator Tube (MGITTM)
(BD, Franklin Lakes, NY, USA), supplemented with
0.8 ml of BD PANTATM (BD, Sparks, MD, USA)
antibiotic mixture and incubated into the BACTECw
MGIT 960MB (BD) instrument using standard
procedures. Primary identification of Mycobacterium
tuberculosis complex was performed on confirmed
positive MGIT tubes using Capilia TB Neo (TAUNS
Laboratory Inc, Shizuoka, Japan), according to the
manufacturer’s instructions. Each positive liquid
culture was confirmed by Ziehl-Neelsen (ZN) stain
and on blood agar plate to check for contamination.
Pure isolates were subcultured into two Löwenstein-
Jensen (LJ) slants, one of which contained sodium
pyruvate, and then incubated at 378C for 8 weeks.
Growth on LJ slants were confirmed as M. tubercu-
losis complex by colonial morphology, ZN stain and
standard biochemical tests. Pure colonies were then
harvested in tryptone soya broth and stored at708C.
LJ slants with no growth after 8 weeks’ incubation
were discarded. All mycobacterial cultures were
identified and confirmed as M. tuberculosis using
standard laboratory procedures.
For the Xpertw MTB/RIF assay, 1.5 ml of Xpert
MTB/RIF Sample Reagent (SR) was added to 0.5 ml
of re-suspended sediment sample and processed
according to the manufacturer’s guidelines.27 The
diluted sample mixture was shaken 10–20 times and
incubated at room temperature for a total of 15 min.
The mixture was then transferred using a sterile
pipette into the open port of a pre-labelled Xpert
cartridge, which was then loaded onto the Xpert
machine. After a 2-h cycle, the results of the Xpert
assay were read and reported as either M. tubercu-
losis 6 rifampicin resistance detected or M. tubercu-
losis not detected.
The Medical Research Council TB Diagnostics
Laboratory holds a Good Clinical Laboratory Prac-
tice Accreditation (ISBN 978-1-904610-00-7), serves
as reference laboratory for the Gambia National TB
Reference Laboratory and subscribes to the UK
National External Quality Assessment Service.
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R E S U M E
C O N T E X T E : Région du grand Banjul en Gambie.
O B J E C T I F : Conduire une évaluation pragmatique du
test Xpertw MTB/RIF dans le diagnostic de la
tuberculose (TB) parmi des enfants-contacts.
S C H É M A : Dans cette étude prospective, un échantillon
de crachats induits a été obtenu de contacts TB âgés de
,15 ans et testé par microscopie fluorescente, culture et
Xpert. L’exactitude du diagnostic des tests
microbiologiques a été évaluée contre la culture et
« tous les diagnostics et traitements de TB » comme
standard de référence séparés.
R É S U LTAT S : En utilisant la culture comme standard de
référence, l’Xpert a été positif pour Mycobacterium
tuberculosis dans 6/14 cas à culture positive et chez 6/
473 enfants à culture négative, soit une sensibilité et une
spécificité de respectivement 42,9% (IC95% 17,7–71,1)
et 98,7% (IC95% 97,2–99,5). En utilisant comme
référence composite standard « diagnostic et traitement
de toutes les TB », l’Xpert et la culture combinés ont été
positifs pour M. tuberculosis chez 20/62 enfants ayant
une TB maladie (32,3% ; IC95% 20,9–45,3), ce qui était
comparable au rendement de la combinaison de la
microscopie, de la culture et de l’Xpert (33,9% ; IC95%
22,3–47,0), mais significativement plus élevé que le
rendement de chacun des tests réalisé isolément.
C O N C L U S I O N S : La sensibilité de l’Xpert est faible chez
les enfants contacts bénéficiant d’un dépistage actif,
mais la combinaison de l’Xpert et de la culture
mycobactérienne augmente les bénéfices en termes de
confirmation bactériologique de la TB maladie.
R E S U M E N
M A R C O D E R E F E R E N C I A: La zona metropolitana de
Banjul en Gambia.
O B J E T I V O: Practicar una evaluación práctica del uso de
la prueba Xpertw MTB/RIF en el diagnóstico de los
contactos pediátricos de los pacientes con tuberculosis
(TB).
M É T O D O S: En el presente estudio prospectivo se obtuvo
una muestra de esputo inducido de los contactos de edad
de ,15 años de pacientes tuberculosos, con la cual se
practicó un examen en microscopio de fluorescencia, un
cultivo y la prueba Xpert. Se evaluó la exactitud
diagnóstica de las pruebas microbiológicas, tomando
como patrones de referencia independientes el cultivo y
una medida compuesta de ‘todos los casos de
diagnóstico y tratamiento de TB’.
R E S U LTA D O S: Al usar el cultivo como referencia, la
prueba Xpert fue positiva para Mycobacterium
tuberculosis en seis de 14 casos con cultivo positivo y
en seis de 473 niños con cultivo negativo y aportó una
sensibilidad de 42,9% (IC95% 17,7–71,1) y una
especificidad de 98,7% (IC95% 97,2–99,5). Al usar
‘todos los casos de diagnóstico y tratamiento de TB’
como patrón de referencia compuesto, la prueba Xpert y
el cultivo combinados fueron positivos para M.
tuberculosis en 20/62 niños con enfermedad
tuberculosa (32,3%; IC95% 20,9–45,3) y exhibieron
un rendimiento comparable al de la combinación de la
microscopia, el cultivo y la prueba Xpert (33,9%;
IC95% 22,3–47,0), pero significativamente superior al
rendimiento de cada prueba utilizada de manera
individual.
C O N C L U S I Ó N: La sensibilidad de la prueba Xpert es
bajo en la investigación activa de los contactos
pediátricos, pero una combinación de la prueba Xpert
y el cultivo de micobacterias ofrece ventajas en la
confirmación bacteriológica de la enfermedad
tuberculosa.
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Isoniazid preventive treatment among child contacts of adults 
with smear-positive tuberculosis in The Gambia
U. Egere,1 A. Sillah,1 T. Togun,1,2 S. Kandeh,1 F. Cole,1 A. Jallow,3 A. Able-Thomas,3 M. Hoelscher,4  
N. Heinrich,4 P. C. Hill,5 B. Kampmann1,6
The current elimination goals for tuberculosis (TB) include a focus on individuals who are latently 
infected with Mycobacterium tuberculosis to reduce the 
number of new TB cases and subsequent M. tuberculo-
sis transmission.1 This strategy requires isoniazid pre-
ventive therapy (IPT) or an alternative regimen. Initial 
targets are those at most risk of disease progression, 
such as young children and human immunodefi-
ciency virus (HIV) infected individuals in contact with 
an infectious adult with TB.2
The above World Health Organization (WHO) rec-
ommendations have not, however, been implemented 
in most of the high-burden TB settings where IPT is 
most needed. In many places where IPT has been im-
plemented and evaluated, the impact is suboptimal 
and the operational challenges are formidable.3–6 Con-
sidering the cascade of care as a whole, it is estimated 
that, even where IPT is part of routine practice, only a 
minority of eligible children complete a course of 
treatment.7 Not only is uptake poor, but adherence 
rates tend to be less than 30% among those who do 
commence IPT.8,9 The measurement of adherence can 
also be unreliable, relying heavily on reports from care 
givers, how often care givers return for more medica-
tion, and pill counts.10,11 Furthermore, interventions 
to improve IPT delivery frequently do not result in im-
proved uptake, adherence and treatment comple-
tion.12 A recent meta-analysis of the cascade of care for 
treatment of latent tuberculous infection (LTBI), 
which indicated where patients get lost in the system 
for various reasons, focused primarily on adults.13
As IPT implementation now has a higher priority 
within the agenda for TB control,14 and as implemen-
tation via TB clinics appears to be challenging, we de-
veloped a home-based IPT programme among child 
contacts of recently diagnosed adult sputum 
smear-positive TB cases and assessed its impact on up-
take, completion and adherence within the cascade of 
care in The Gambia. We also measured the isoniazid 
(INH) metabolites in urine to assess the reliability of 
our adherence measures.
METHODS
Study sites
The study was carried out in the Greater Banjul area of 
The Gambia between November 2013 and May 2015. 
This is a mixed urban-to-rural area, including the capi-
tal city of Banjul, and has a population of approxi-
mately 700 000. The setting has been described 
elsewhere.15
Participants
Child contacts aged 5 years living in the same 
household as adult sputum smear-positive TB cases 
were recruited. A household was defined as a group of 
individuals eating from the same pot and living in the 
same building.16
Symptom screening, tuberculin skin testing and 
clinical evaluation
Adults with newly diagnosed sputum smear-positive 
TB were identified at the National Leprosy/TB Control 
Programme (NLTP) clinics and were asked for their 
consent to a household visit. After the project was ex-
plained to the parents/care givers, written informed 
consent was obtained. A standard symptom-screening 
questionnaire for TB was then administered to ascer-
tain if any child living in the same household had a 
cough of 2 weeks’ duration in association with at 
least one of the following symptoms: weight loss, fail-
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Setting: Greater Banjul area of The Gambia.
Objectives: To evaluate uptake, adherence and comple-
tion of treatment among tuberculosis (TB) exposed chil-
dren in The Gambia when isoniazid preventive treatment 
(IPT) is delivered at home
Design: Child (age 5 years) contacts of adults with 
smear-positive TB were prospectively enrolled. Following 
symptom screening, tuberculin skin testing and clinical 
evaluation where indicated, those without disease were 
placed on daily isoniazid, provided monthly at home. Ad-
herence was assessed by pill counts and IsoScreen™ 
urine test.
Results: Of 404 contacts aged 5 years, 368 (91.1%) 
were offered IPT. Of the 328 (89.4%) for whom consent 
was received and who commenced IPT, 18 (5.5%) 
dropped out and 310 (94.5%) remained on IPT to the 
end of the 6-month regimen. Altogether, 255/328 chil-
dren (77.7%, 95%CI 73.2–82.2) completed all 6 months, 
with good adherence. The IsoScreen test was positive in 
85.3% (435/510) of all tests among those defined as hav-
ing good adherence by pill count and in 16% (8/50) of 
those defined as having poor adherence (P  0.001). A 
cascade of care analysis showed an overall completion 
rate with good adherence of 61% for all child contacts.
Conclusion: Home-delivered IPT among child contacts 
of adults with smear-positive TB in The Gambia achieved 
verifiable high uptake and adherence rates. System rather 
than patient factors are likely to determine the success of 
IPT at national level.
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ure to gain weight, fever or night sweats. The tubercu-
lin skin test (TST) was performed using the Mantoux 
method (2 tuberculin units of purified protein deriva-
tive RT23, Statens Serum Institute, Copenhagen, Den-
mark) and read 48–72 h later. A positive TST was de-
fined as an induration of 10 mm, in line with WHO 
recommendations.17 Child contacts with symptoms 
suggestive of TB and/or a positive TST were referred to 
a dedicated childhood TB clinic for further evaluation. 
All children diagnosed with TB disease were referred to 
the TB clinics of the NLTP for DOTS-based treatment.
Isoniazid prophylaxis and follow-up
All child household contacts aged 5 years in whom 
TB disease was excluded were provided with IPT at 10 
mg/kg/day for 6 months, as recommended by the 
WHO,2 regardless of their TST result. Field workers de-
livered the IPT to the homes of the children on a 
monthly basis and administered a brief questionnaire 
to capture missed doses, the reasons for missed doses 
and any adverse events from the medication. To mea-
sure adherence, pill counts were performed for all chil-
dren. An IPT card was specifically developed to record 
the child’s weight and the number of unconsumed 
doses of medication. All children were assessed every 3 
months for 1 year; those with new symptoms sugges-
tive of TB were referred to the childhood TB clinic at 
the Medical Research Council (MRC) unit. A final 
home visit was made 1 year after INH completion to 
ascertain post-IPT status.
IsoScreen testing
In the first year of the study, consecutively recruited 
children on IPT were asked to provide a monthly urine 
sample for a qualitative assessment of adherence using 
the IsoScreenTM test (GFC Diagnostics Ltd, Oxford-
shire, UK), a point-of-care colorimetric assay that de-
tects INH and its metabolites utilising a disposable 
plastic test device and the Arkansas method for metab-
olite detection.18 Two ml of collected urine was in-
jected into a reaction chamber and mixed with the re-
agents contained in an effervescent tablet for about 
10 s. Dark blue/purple colouration appearing within 5 
min indicates a positive result, i.e., the individual has 
taken INH within the previous 24–48 h. If no INH has 
been taken, the colour of the urine remains un-
changed, indicating a negative result. Care givers were 
informed about the monthly visits, but the actual days 
of the visit were unannounced. The results of the Iso-
Screen testing were recorded on the child’s INH card.
Ethics approval
Ethics approval for the study was obtained from the 
joint Medical Research Council/Gambian government 
ethics committee (Ref. L2012.E01), Banjul, The 
Gambia.
Data analysis
Data were double-entered into an Access database (Mi-
crosoft Corp, Redmond, WA, USA) and verified using 
consistency checks. All analyses were performed using 
STATA/IC 13.1 (StataCorp, College Station, TX, USA). 
IPT implementation was assessed using a cascade of 
care approach. To provide a denominator for the up-
take component of the cascade, the number of con-
tacts of those TB cases who refused a home visit and 
the number of children with TB disease among those 
who had not been assessed in the clinic were esti-
mated. This was performed by simple extrapolation of 
the average number of child contacts per case and the 
rate of disease in those assessed to a rate of disease in 
those not assessed, rounded to the nearest whole num-
ber.13 Adherence was divided into three categories: 
good, reasonable and poor, if respectively 80%, 60–
80% or 60% of the pills delivered each month had 
been taken.19 Treatment completion was defined as 
consuming 80% of all pills prescribed in each of the 
6 months of prophylaxis.20 The proportion of children 
with a positive IsoScreen test result was compared 
among the adherence categories using the χ2 test. The 
data are presented in frequencies, proportions and per-
centages with their 95% confidence interval (CI).
RESULTS
IPT uptake and characteristics of those 
commenced on IPT
Over the study period, 301/330 adults with sputum 
smear-positive TB consented to contact tracing in their 
households. Altogether 404 children aged 5 years 
and living in the same household as an adult index 
case were screened at community level. Of these, 163 
symptomatic and/or TST-positive children were re-
ferred for further evaluation in the clinic, and 153/163 
(94%) attended the appointment. Of this group, 26 
(16.9%) were diagnosed with active TB. The remaining 
368 children were eligible for IPT and consent was 
sought from their parent or legal guardian, of whom 
25 refused, 14 moved out of the study area after con-
senting and one child died of a brief febrile illness 
thought to be malaria in the first month of prophy-
laxis (Figure 1). Of 328 children initiated on IPT, 50.6% 
were females; the median age (interquartile range 
[IQR]) at recruitment was 2.3 years (IQR 1.3–3.4) 
(Table 1).
Completion of IPT
Of the 328 children commenced on IPT, 318 (96.9%) 
started within 1 month of the diagnosis of their re-
spective index cases. IPT was administered by the 
mothers in 92.3% (303/328) of the cases, by the fa-
thers in 2.4% (8/325), and by grandmothers and sib-
lings in 0.9% of cases each.
Eighteen of the 328 children dropped out of IPT, 
leaving 310 children remaining on prophylaxis at the 
end of 6 months. There was no difference in the char-
acteristics of those who dropped out and those who 
completed prophylaxis. A final 255 of the 328 children 
(77.7%, 95%CI 73.2–82.2) completed the 6 months of 
IPT with good adherence.
Adherence to treatment
During the study period, 59 040 doses of IPT were dis-
pensed, of which 53 573 (90.7%) were consumed. 
Based on pill counts, 78.9% (95%CI 74.5–83.2) of all 
medications were consumed by children with good ad-
herence, 15.4% (95%CI 11.5–19.3) by children with 
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reasonable adherence, and 5.6% (95%CI 3.1–8.1) by children with 
poor adherence. Table 2 shows the monthly adherence of chil-
dren on IPT as determined by pill count. Less than 10% of chil-
dren on prophylaxis in any month had poor adherence. Overall, 
the proportion of children with positive IsoScreen test results was 
similar to the proportion with good adherence: good adherence 
by pill count was 77.4% (95%CI 74.2–80.6) compared to 76.6% 
(95%CI 73.4–79.8) with positive urine test results.
The proportion of children with good adherence remained 
high, at 76.2% in the first month, and increased gradually over 
time to 83% in month 6. Spot urine samples were collected from 
the first 141 children recruited into the study, and 658 episodes of 
pill counts and urine tests were carried out simultaneously. 
Among these children, 85.3% (435/510) of all tests among those 
defined as having good adherence by pill count were positive, 
compared to 16% (8/50) of tests among those defined as having 
poor adherence (P  0.001). Over the 6 months of IPT, 80.6–
93.3% of those with good adherence by pill count were also posi-
tive by IsoScreen, compared to 0–25.0% of those with poor adher-
ence (Table 3). Across the three adherence categories there was a 
significant trend in IsoScreen positivity (P  0.002) in each 
month of IPT. 
Of 314 responses to the adherence questionnaire adminis-
tered among care givers, 247 (78.7%) stated that the main reason 
for failure to administer the pills was forgetfulness. The second 
major reason, given by 30 (9.6%) of the care givers, was travel. 
Other reasons included the child being sick (11 [3.5%]), refusing 
medication (7 [2.2%]) and misplacement of the medications (5 
[1.6%]).
Side effects
No side effects were reported throughout the study period.
One-year follow-up
Of the 310 children who completed their course of IPT, 12 (3.9%) 
were lost to follow-up at 1 year after IPT. One child aged 18 
months died of a sudden febrile illness not related to INH or TB. 
One child who dropped out of IPT in the first month developed 
clinically diagnosed TB by the ninth month of follow-up. All the 
other children remained well.
Cascade of care summary analysis
To identify where improvements may be needed in the contin-
uum of care of child contacts eligible for IPT, we used a cascade of 
care approach, as summarised in Figure 2. We estimated uptake 
and completion of IPT among all eligible children in the house-
holds of the 330 adults with TB approached during the study. Af-
ter excluding 27 children with TB disease (26 diagnosed after clin-
ical evaluation and one estimated from among those who failed 
to attend the clinic), 418 children remained eligible for IPT, of 
whom 328 (78.5%) accepted IPT and 255 (61%) completed 6 
months of IPT with good adherence.
DISCUSSION
In this study, we implemented and evaluated a home-based IPT 
programme in The Gambia. Uptake of IPT was high (78%), and 
77.7% of all child contacts who initiated IPT completed the 
6-month course with good adherence. A further 15.4% had rea-
sonable adherence, and 5.6% had poor adherence. We also found 
that pill count reliably reflected adherence in this population. 
The most frequent reason for non-adherence was forgetfulness. 
The cascade of care analysis showed that approximately 61% of 
the estimated original number of contacts eligible for IPT com-
pleted 6 months of IPT with good adherence, and provides in-
sight into the potential public health impact of the programme.
Adherence is a major determinant of efficacy of IPT.21 High IPT 
uptake in The Gambia is encouraging as the country moves to ex-
pand these services nationwide. In high TB burden countries, the 
proportion of those commencing and completing at least 4 
months of IPT is approximately 15%,6,7 and even in research con-
ditions adherence to unsupervised IPT in high-burden countries 
has been relatively low. Good adherence to IPT was achieved by 
approximately 24% in South Africa,4,22 25.6% in Indonesia8 and 
32.5% in Southern Ethiopia.9 In contrast, in another research 
study conducted in Guinea Bissau, West Africa, where IPT was 
also delivered to the homes of child contacts for 9 months, the 
proportion achieving good adherence according to pill counts 
was 76%,20 similar to our study. Interestingly, when INH was de-
livered at home to children in Ethiopia, adherence was very poor, 
with only 33% of children taking their medications for up to 4 
FIGURE 1 Flow chart of screening and recruitment of children on 
INH prophylaxis. INH = isoniazid; TB = tuberculosis.
TABLE 1 Characteristics of children placed on INH prophylaxis
Characteristics n (%)
Age at recruitment, years, median [IQR] 2.3 [1.3–3.4]
Weight at recruitment, kg, median [IQR] 11.3 [9–13.3]
Females 167 (50.9)
TST result
 Negative (10 mm) 265 (80.8)
Ethnicity
 Mandinka 155 (47.3)
 Fula 58 (17.7)
 Jola 59 (18.0)
 Wolof 27 (8.2)
 Other 29 (8.8)
Relationship to index case
 Child 108 (33.2)
 Sibling 18 (5.5)
 Other* 166 (51.1)
 Not related 33 (10.2)
* Includes cousin, nephew, niece or other extended family member.
INH = isoniazid; IQR = interquartile range; TST = tuberculin skin test.
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months.9 More site-specific research is required to identify the 
best locally applicable approach to optimise adherence.23
The understanding and willingness shown by carers, especially 
mothers, to administer IPT provides a potential solid base for pro-
grammatic home-delivered IPT. As the project is now being trans-
ferred to the government programme, the priority is to enable 
sustained delivery of INH to homes of child contacts. In the cur-
rent organisation of the health system in The Gambia, commu-
nity health workers and assistants living within the communities 
play a major role in public health. It is intended to provide train-
ing for this group to deliver IPT—and monitor IPT delivery—to 
homes of contacts at minimal or no additional cost to the NTP, as 
they are already involved as TB treatment supporters to the index 
cases.
The use of IsoScreen enabled us to objectively assess whether 
pill counts are a reliable way to assess adherence in The Gambia, 
and we found excellent agreement. Our results should be inter-
preted with caution, however, as some of the negative test results 
came from individuals with good adherence by pill count but 
who had missed doses only in the most recent days. The sensitiv-
ity of the IsoScreen test decreases with the passage of time from 
ingestion of the medication.24 Similarly, some poorly adherent in-
dividuals may have taken IPT prior to their IsoScreen test. As the 
day for IsoScreen testing was not announced in advance, how-
ever, it is unlikely that differential bias was introduced. A negative 
IsoScreen result has been reported in fast acetylators;25 we did not 
assess acetylator status.
In summary, the uptake of and adherence to IPT in our study 
were high by international standards, suggesting that system 
rather than patient factors will be the main determinants of suc-
cess when IPT management is transferred to be fully operational 
under the NLTP. IPT was highly acceptable to care givers and 
children in The Gambia, and home delivery will present an op-
portunity for health education on TB and other topics of public 
health importance, such as malnutrition, sanitation and oral re-
hydration. Training of health workers in childhood TB and IPT 
will be required to ensure success.26,27 The cascade of care sum-
mary showed that there are opportunities for improvement for 
the IPT programme to have maximal public health impact. Fur-
ther studies could explore the reasons why some households do 
not uptake IPT and whether an intervention to reduce care giver 
forgetfulness, such as cell phone text reminders,28 could be 
beneficial.
TABLE 2 Adherence to INH prophylaxis determined by monthly pill count
Month 
Patients on IPT at 
end of month
(N = 328)
n
Good 
adherence
n (%)
Reasonable 
adherence
n (%)
Poor 
adherence
n (%)
1 323 246 (76.2) 49 (15.2) 28 (8.8)
2 316 245 (77.5) 49 (15.5) 22 (6.9)
3 316 245 (77.5) 53 (16.8) 18 (5.7)
4 302 235 (77.8) 51 (16.9) 16 (5.3)
5 311 252 (81.0) 52 (16.7) 7 (2.3)
6 310 259 (83.6) 36 (11.6) 15 (4.8)
INH = isoniazid; ITP = isoniazid preventive therapy.
FIGURE 2 Cascade of care of child contacts eligible for IPT. IPT = 
isoniazid preventive therapy.
TABLE 3 Adherence by pill count and urine test result in the 
IsoScreen™ cohort
Month of 
prophylaxis*
Adherence 
category
Patients
N (%)
Positive IsoScreen
n/N (%)
1 (n = 120) Good 97 (80.7) 82/97 (85.5)
Reasonable 11 (9.2) 4/11 (36.4)
Poor 12 (10.1) 2/12 (16.7)
2 (n = 141) Good 105 (74.5) 90/105 (85.7)
Reasonable 25 (17.7) 14/25 (56.0)
Poor 11 (7.8) 1/11 (9.1)
3 (n = 134) Good 103 (76.9) 83/103 (80.6)
Reasonable 19 (14.2) 12/19 (63.2)
Poor 12 (8.9) 4/12 (33.3)
4 (n = 107) Good 87 (81.1) 74/87 (85.1)
Reasonable 14 (13.2) 9/14 (64.3)
Poor 6 (5.7) 0/6 (0)
5 (n = 96) Good 75 (78.1) 66/75 (88.0)
Reasonable 16 (16.7) 13/16 (81.3)
Poor 5 (5.2) 0/5 (0)
6 (n = 60) Good 45 (75) 42/45 (93.3)
Reasonable 11 (18.3) 8/11 (72.7)
Poor 4 (6.7) 1/4 (25.0)
* The IsoScreen test was used only during the first 12 months of the study in the 
same children; the number of children willing to give urine declined substantially 
despite the dropout rate remaining very low.
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Contexte  :  Région du Grand Banjul en Gambie.
Objectifs  :  Evaluer la couverture, l’adhésion et l’achèvement du 
traitement parmi des enfants exposés à la tuberculose (TB) en 
Gambie quand le traitement préventif par isoniazide (TPI) est donné 
à domicile.
Schéma  :  Les enfants âgés de 5 ans, contacts d’adultes atteints de 
TB à frottis positif, ont été enrôlés de manière prospective. Après 
dépistage sur les symptômes, test cutané à la tuberculine et 
évaluation clinique quand cela était indiqué, les enfants non malades 
ont été mis sous isoniazide, fourni une fois par mois à domicile. 
L’adhésion a été évaluée par un comptage des comprimés et par un 
test urinaire IsoScreen™.
Résultats  :  Sur 404 contacts âgés de 5 ans, 368 (91,1%) ont été 
invités à bénéficier du TPI, et 328 (89,4%) ont consenti et commencé 
le TPI. Sur ces 328 enfants, 18 (5,5%) ont abandonné et 310 (94,5%) 
sont restés sous TPI jusqu’à la fin du 6e mois. Au total, 255/328 
enfants (77,7% ; IC95% 73,2–82,2) ont achevé les 6 mois de 
traitement avec une bonne adhésion. Le test IsoScreen a été positif 
chez 85,3% (435/510) de tous les tests parmi ceux définis comme 
ayant une bonne adhésion par le comptage des comprimés et chez 
16% (8/50) de ceux définis comme ayant une adhésion médiocre 
(P  0,001). L’analyse de la « cascade des soins » a montré, pour tous 
les enfants contacts, un taux de bonne adhésion d’ensemble de 61%.
Conclusion  :  L’administration à domicile du TPI à des enfants contacts 
d’adultes atteints de TB à frottis positif en Gambie a abouti à une 
bonne couverture et à un bon taux d’adhésion, tous deux vérifiables. 
Ce sont les facteurs de système plutôt que ceux liés au patient qui 
sont susceptibles de déterminer le succès du TPI au niveau national.
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Marco de referencia: La zona del Gran Banjul en Gambia.
Objetivos: Evaluar la aceptación del tratamiento preventivo con 
isoniazida (TPI), su cumplimiento y su compleción por parte de los 
niños expuestos en Gambia, cuando se suministra el tratamiento en 
los hogares.
Método: Se incluyeron en el estudio de manera prospectiva los 
niños menores de 5 años de edad que eran contactos de un adulto 
con diagnóstico de tuberculosis (TB) y baciloscopia positiva. Luego 
de la detección sistemática a partir de los síntomas, se practicaron la 
prueba cutánea de la tuberculina y la evaluación clínica cuando 
estaban indicadas; en caso de ausencia de enfermedad activa se inició 
el tratamiento diario con isoniazida, la cual se suministraba en el 
hogar cada mes. Se evaluó el cumplimiento en función del recuento 
de los comprimidos y la prueba IsoScreen™ en muestras de orina.
Resultados: En los 404 contactos menores de 5 años de edad, se 
ofreció el TPI a 368 niños (91,1%) y 328 lo aceptaron y comenzaron 
a recibirlo (89,4%). De este grupo, 18 niños abandonaron el 
tratamiento (5,5%) y 310 recibían aun el medicamento al final del 6 
mes (94,5%). De los 328 niños, 255 terminaron los 6 meses de 
tratamiento, con un cumplimiento satisfactorio (77,7%; IC del 95% 
de 73,2 hasta 82,2). La prueba IsoScreen fue positiva en el 85,3% 
(435/510) de los casos definidos con cumplimiento adecuado según 
el recuento de comprimidos y en el 16% (8/50) de los casos cuyo 
cumplimiento se consideró deficiente (P  0,001). El análisis de la 
trayectoria asistencial reveló que en todos los contactos la tasa global 
de compleción con cumplimiento satisfactorio fue 61%.
Conclusión: El TPI suministrado en el hogar a los niños que son 
contactos de un adulto con diagnóstico de TB y baciloscopia positiva 
alcanza altas tasas de aceptación y de cumplimiento que se pueden 
verificar. Los factores que determinan el éxito del TPI a escala nacional 
dependen del sistema de salud y no del paciente.  
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Statement of contribution 
I led a team of clinicians, nurses, field and laboratory staff who participated in the household 
contact tracing and tuberculin skin testing in the communities, clinical assessment in the 
clinic, sputum and blood sample collection and processing, administration and management 
of isoniazid prophylaxis, data management and follow up of the enrolled cohort of children. 
Specifically, I managed the field and clinical research activities on a day to day basis, 
conducted clinical examination on all child TB suspects referred from the field, read and 
interpreted chest X rays and made diagnosis of TB. I took personal responsibility for ruling 
out TB disease and prescribing isoniazid prophylaxis to eligible children. A junior research 
clinician, who also stood for me and managed the field and clinic activities when I attended 
the Modules in Munich, supported my work. 
 
I collected qualitative and quantitative data, worked with the project data manager in cleaning 
and verification of the datasets, and conducted the analysis under the supervision of Prof 
Kampmann, Prof Hoelscher, Dr Heinrich and the additional available expertise at the MRC 
Unit in Epidemiology and data management. 
 
After deciding on the papers to be published from our work with my supervisors, I undertook 
the analysis of the relevant data wrote up the first draft of the first author papers and managed 
the process of senior author review and reviewers’ comments. I presented parts of my data at 
local and international conferences, as well as in MRC Unit academic seminars. 
 
Throughout the period of the project, I represented the Childhood TB Program in meetings 
with the Gambian National TB Program. 
 
 
 49 
10. Acknowledgements 
I would like to thank my local supervisor, Prof Beate Kampmann, for her exceptional, 
brilliant and outstanding approach to supervision, which ensured I got on top of all the 
aspects of this PhD training. She consistently motivated me and maintained an incredible turn 
around time with every material submitted to her for review. She maintained without a break, 
throughout the period of this PhD, our two weekly chats to discuss the progress of my 
research work, data analysis and manuscript preparation, and the challenges around field and 
clinic work. She was proactive in providing unflinching support to ensure I fulfilled in a 
timely manner, all the requirements for completing this PhD. 
My gratitude also goes to my direct supervisor, Dr Norbert Heinrich for his invaluable inputs 
and guidance. He visited and spent sometime with me in the research field and maintained 
constant communication throughout the period of this PhD. He went the extra mile to liaise 
on my behalf, on many occasions, with the coordinating team at the CIH, whenever the need 
arose.  He prioritized my research period reports and provided a timely review of manuscripts 
and the thesis summary. I drew a lot of encouragement from his personal messages to me in 
time of personal challenges. In the same vein, I thank Prof Michael Hoelscher, my habilitated 
supervisor, for the solid foundation he laid during the module blocks and for ongoing senior 
oversight he provided throughout the PhD.  
My PhD would have been impossible without the solid support of my colleagues at the MRC 
Gambia. I thank Dr Abdou K Sillah for competently holding the fort at the Childhood TB 
program and ensuring the research project went on undisturbed during my module blocks in 
Munich. He continued to provide invaluable support in the field and clinic. I thank Dr Toyin 
Togun for his immense support especially in critical appraisal and analysis of data, 
manuscript critique and review, and for generally being there for me. I thank Dr Uduak 
Okomo who, apart from contributing to the critique of my research work, also supplied 
technical assistance with the preparation of various documents i worked with during this 
PhD, including this thesis summary. My colleague in the TB research platform, Dr Owolabi, 
was readily available for discussion and solving of various day to day clinic challenges and 
provided independent opinion on management of concurrent illnesses in the child contacts 
seen in the clinic. 
 I thank the field team at “Reach4Kids”led by Monica Davies and Abdoulie Tunkara for their 
dedication, understanding and support. They worked within and outside regular work hours 
 50 
to ensure that recruitments, clinical evaluation and follow ups were conducted in a timely 
fashion. Njilan Johnson from the MRC research support office was the arrowhead of my PhD 
research support. I am immensely grateful. 
My gratitude also goes to the National Leprosy and Tuberculosis Control Program of The 
Gambia for their ongoing support, which positively impacted this PhD work. The PhD 
research period was yet another opportunity to continue our ongoing relationship with our 
study communities and the families affected by tuberculosis. I therefore thank all our 
parents/caregivers and their children without whose cooperation and support this research 
project would not have been undertaken in the first place. 
I would like to thank my family for going through it all with me.  I thank my lovely wife and 
best friend, Ifunanya, for her inestimable role; the strong belief in me, the patience, the 
constant support; the resilience in time of stress and the radiance that kept me bright. 
Finally, I give thanks to God for being, to me, ‘the eye which never sleeps beneath the wings 
of night; the ear which never shuts when sink the beams of light”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
11. Annex 
 
 
 
 
 
 
 
 
Egere Uzochukwu
From: onbehalfof+annekeh+sun.ac.za@manuscriptcentral.com on behalf of The International 
Journal of Tuberculosis and Lung Disease 
[onbehalfof+annekeh+sun.ac.za@manuscriptcentral.com]
Sent: 20 September 2016 11:46
To: Egere Uzochukwu
Cc: annekeh@sun.ac.za; ijtld@theunion.org; kathy.deriemer@gmail.com
Subject: IJTLD - Decision on Manuscript ID IJTLD-04-16-0289.R1
20‐Sep‐2016 
Dear Dr. Uzochukwu Egere 
Thank you for sending us the revised version of your article entitled 
"Identifying children with tuberculosis among household contacts in The Gambia" (Original 
Article) 
and your reply to the reviewers' comments. 
I am pleased to inform you that your manuscript has been accepted for publication in one of 
the forthcoming issues of the IJTLD, subject to the usual editorial revisions. 
Your article will be checked before being prepared for publication, and you will be contacted 
by the Editorial Office if there are any elements missing. 
If you have any queries, please contact the Editorial Office at ijtld@theunion.org. Remember 
to include the IJTLD number of your accepted manuscript in the subject line of your e‐mail. 
With kind regards, 
Sincerely, 
Prof. Anneke Hesseling 
Associate Editor 
IJTLD 
Please Note: 
1. An electronic copyright form must be supplied by each listed author. All authors will now
be contacted so that they can log on and complete the form on Manuscript Central. No article 
can be published until a form has been submitted by each author. 
2. Articles must comply in terms of length with journal requirements for their submission
category, otherwise authors may be asked to make modifications before their article can be 
published.  Authors whose articles are over length (e.g., over 6 pp for original articles) 
will incur charges of 200€/page. 
3. Articles can be made Open Access at the time of online publication, for a charge of 1500€.
‐ If for funding reasons an article requires a Creative Commons Attribution (CC‐BY) license 
and/or deposit onto Europe PMC/PMC, the author should inform the Editorial Office. 
The IJTLD Instructions to Authors can be viewed on the ScholarOne Manuscripts website 
(http://mc.manuscriptcentral.com/ijtld)  or on the Union website (http://www.theunion.org). 
From: onbehalfof+pha+theunion.org@manuscriptcentral.com on behalf of Public Health Action
To: Egere Uzochukwu; Sillah Abdou; toyin.togun@mail.mcgill.ca; Kandeh Sheriff; Cole Fatoumata;
adamahaddyjatou@gmail.com; annaable_thomas@hotmail.com; hoelscher@lrz.uni-muenchen.de;
heinrich@lrz.uni-muenchen.de; philip.hill@otago.ac.nz; Kampmann Beate
Subject: Manuscript PHA-08-16-0073
Date: 29 August 2016 11:58:29
Dear Authors
Your manuscript entitled
"Isoniazid Preventive Treatment among Child Contacts of Adults with Smear Positive Tuberculosis in
The Gambia"
has been successfully uploaded to Public Health Action. It will now be checked by the Editorial
Office and released to the editor for assignment of reviewers.
Your manuscript number is: PHA-08-16-0073. Any correspondence concerning the article should
have this number in the subject line, and should be sent to cpierard@theunion.org.
This  message has also been sent to your corresponding author, who is responsible for all
communications regarding the paper.
Please note that if the article is accepted for publication, you will be asked to log onto the site to
submit an electronic copyright form.
Thank you for your interest in Public Health Action.
Sincerely,
The Editorial Office
PHA
53
 54 
 
Curriculum Vitae 
   
Uzochukwu Emeka Egere 
House 12, Medical Research Council Quarters, Atlantic Boulevard, Fajara, Banjul The Gambia 
+2204495442 ext 3029 Mobile: +2207666189 
uegere@mrc.gm 
Nigerian 
14.08.1970 
Male 
 
Work experience 
October 2011 -  current 
Lead Clinician and Coordinator, Childhood TB studies, Medical research council (UK), Gambia 
 March 2011 – September 2011 
 Research Clinician, Pneumococcal conjugate vaccine impact studies, Medical research Council (UK), 
Gambia 
August 2006 – February 2009,  
Research Clinician, Pneumococcal carriage studies, MRC (UK), Gambia 
 
Education and training 
October 2013 - current 
PhD student, Medical Research-International Health, Ludwig-Maximilian University, Munich, Germany 
February 2009 – December 2010 
Masters degree in Public Health, University of Otago, New Zealand 
September 1998 – March 2005 
Fellowship of the West African College of Physicians (Paediatrics), University College Hospital, Ibadan, 
Nigeria 
September 1987 – March 2005 
Bachelor of Medicine, Bachelor of Surgery, University of Jos, Nigeria 
Social skills and competences 
I have gained professional experience in Nigeria, The Gambia and Germany at both practical level in 
patient management and fieldwork as a Paediatrician and researcher as well as within academic 
environments of Nigerian Universities, The MRC Gambia, University of Tuebingen, Germany and the 
University of Otago – a mix of experience in different continents. I have participated in and directed 
clinical and research work as both junior doctor and senior clinician in these settings. These exposures have 
provided me the opportunity to develop the ability to interact and work together with people of diverse 
backgrounds.  
 55 
List of Publications 
 
Egere U, Togun T, Sillah A K, Mendy F et al: Identifying children with tuberculosis 
among household contacts in The Gambia.  International Journal of Tuberculosis and Lung Disease
 21 (1): 46 - 52
  
Toyin T, Egere U and Beate Kampmann. “Extrapulmonary manifestations of tuberculosis and 
tuberculosis in immunocompromised children” in European Respiratory Society (ERS) 
HERMES Handbook, Paediatric Respiratory Medicine (2013), Vol. 12; Chapter 8, pp 284-
292  
 
Toyin T, Egere U and Kampmann B. “Childhood tuberculosis: new tools and remaining 
challenges.” Recent Advances in Paediatrics (2014), Vol 26; Chapter 1, pp 1-10 
 
Togun TO, Egere U, Gomez MP, Sillah AK, Daramy M, Tientcheu LD, et al. No added value 
of interferon-γ release to a prediction model for childhood tuberculosis. European 
Respiratory Journal. 2016;47(1):223-32. 
 
Togun T, Egere U, Sillah A, Ayorinde A, Mendy F, Tientcheu L, et al. Contribution of 
Xpert® MTB/RIF to the diagnosis of pulmonary tuberculosis among TB-exposed children in 
The Gambia. The International Journal of Tuberculosis and Lung Disease. 2015;19(9):1091-
7. 
 
Egere U, Townend J, Roca A, Akinsanya A et al. Indirect effect of 7-valent pneumococcal 
conjugate vaccine on pneumococcal carriage in newborns in rural gambia: a randomised 
controlled trial. PLoS ONE 01/2012; 7(11): e49143 
 
Roca A, Hill PC, Townend J, Egere U et al: Effects of community-wide vaccination with PCV-7 on 
pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Medicine 
10/2011; 8(10):e1001107. 
 
Egere U, Sillah A K, Togun T, Cole F et al: Isoniazid preventive treatment among child 
contacts of adults with smear positive tuberculosis in The Gambia. Public Health Action 
 2016; 6(4): 226 - 231 
 
 
 
 
 
 
 
 
 
 
 
 
